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ABSTRACT 
Afferent lymphatic vessels transport leukocytes and soluble molecules from the 
periphery to lymph nodes. These vessels are lined with lymphatic endothelial cells 
(LEC), which are also present in lymph node sinuses. Lymph nodes are centers for 
the initiation of immune reactions, where antigen presenting cells present foreign 
antigens to naïve lymphocytes. Lymph-borne antigens are sorted based on their 
size in the subcapsular sinus (SCS) of the lymph node and only small antigens get 
direct access to the lymph node parenchyma. Lymphocytes migrate constantly into 
lymph nodes in search of foreign antigens. After searching for their cognate 
antigens, lymphocytes leave the nodes by egressing at the lymph node medullary 
sinus and the efferent lymphatics.  
LECs are known to regulate cell entry into lymph nodes as well as lymphocyte 
egress at the medullary sinus. The differences between the two populations of 
lymph node LECs, namely the afferent and efferent lymphatics, have not been 
thoroughly investigated. My doctoral studies describe two new molecules 
expressed in the afferent and efferent lymphatics (Msr1 and Robo4) and their role 
in lymphocyte migration. We also investigated how large antigens and antibodies 
get access into the lymph node parenchyma. Msr1 and Robo4 regulate lymphocyte 
migration and turnover in peripheral lymph nodes and Peyer’s patches. Moreover, 
we discovered that LECs transcytose large antigens and antibodies instantly into 
the lymph node parenchyma. These studies broaden the current view of LECs as 
regulators of cell and molecular trafficking at the lymph node sinuses. Our results 
also suggest that the effective delivery of lymph-borne antibodies into lymph nodes 
may be therapeutically harnessed. 
KEYWORDS: lymphatic endothelial cells, lymph node, lymphocyte migration, 
Msr1, Robo4, antibody transcytosis  
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TIIVISTELMÄ 
Imusuonet kuljettavat valkosoluja sekä liukoisia molekyylejä perifeerisistä 
kudoksista imusolmukkeisiin. Lymfaattiset endoteelisolut verhoavat sekä suonien 
että imusolmukkeen onteloiden sisäpintoja. Imusolmukkeet ovat tärkeitä keskuksia, 
joissa elimistön immuunireaktiot saavat alkunsa. Antigeenejä esittelevät valkosolut 
esittelevät vieraat molekyylit lymfosyyteille, mikä saa aikaan niiden aktivoitu-
misen. Imunesteessä olevat antigeenit lajitellaan koon mukaan imusolmukkeen 
subkapsulaarisinuksessa ja vain pienillä molekyyleillä on pääsy imusolmukkeen 
sisäosiin. Lymfosyytit kiertävät jatkuvasti imusolmukkeissa etsien vieraita anti-
geenejä ja poistuvat imusolmukkeesta medullaarisinuksen vieviä imusuonia pitkin. 
Lymfaattiset endoteelisolut säätelevät valkosolujen pääsyä imusolmukkeeseen 
sekä niiden pois lähtöä medullaarisinuksessa. Imusolmukkeessa olevien tuovien ja 
vievien endoteelisolujen eroja ei ole aikaisemmin kuvattu. Väitöskirjassani tutkin 
kahden uuden lymfaattisissa endoteelisoluissa ilmennettävän molekyylin (Msr1, 
Robo4) merkitystä valkosoluliikenteen säätelyssä. Selvitimme myös, miten suuret 
antigeenit sekä vasta-aineet pääsevät imusolmukkeen sisäosiin. Sekä Msr1 että 
Robo4 säätelevät lymfosyyttien kulkua niin perifeerisissä kuin suoliston pinnan 
imusolmukkeissa. Lymfaattiset endoteelisolut myös kuljettavat aktiivisesti suuria 
antigeenejä sekä vasta-aineita imusolmukkeen sisäosiin. Väitöskirjani tulokset 
laajentavat käsitystämme lymfaattisten endoteelisolujen merkityksestä imusolmuk-
keen liikenteen säätelijöinä. Tutkimukseni tuloksia vasta-aineiden kulkemisesta 
imuteitä pitkin imusolmukkeisiin voidaan myös hyödyntää terapeuttisesti. 
AVAINSANAT: lymfaattiset endoteelisolut, imusolmuke, lymfosyyttiliikenne, 
Msr1, Robo4, vasta-aineiden transsytoosi  
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1 Introduction 
Immune cell migration is vital for our health. Our immune system is constantly 
surveilling the body for pathogens, foreign antigens and other malignant cells for it 
to target and eliminate. In order to find these harmful agents, immune cells migrate 
throughout the body via the blood and lymphatic vasculature. The lymphatic 
system contains lymph nodes that are attached to one another by lymphatic vessels. 
These secondary lymphoid organs are reactive centers, where adaptive immune 
responses are initiated. Lymphocytes migrate into lymph nodes in order to 
recognize foreign antigens. When encountering them, lymphocytes become 
activated and are trained to attack and eliminate these agents in protection of the 
host. For successful immune reactions to take place, migration of immune cells 
must be tightly regulated. In addition, the transport of foreign antigens to sites of 
immune recognition has to be carefully guided. (von Andrian and Mempel, 2003; 
Randolph et al., 2017) 
Naïve lymphocytes migrate into lymph nodes mainly via the blood vasculature, 
whereas antigens, antigen-presenting cells and other lymphocyte subpopulations 
migrate into lymph nodes via lymphatic vessels. Not only does the lymph node 
harbor immune cells, it also acts as a filter that determines which molecules present 
in lymph are able to enter the node. Small soluble molecules drain into the lymph 
node parenchyma within a specialized reticular conduit system, while large 
antigens only get access to the lymph node within migratory dendritic cells (DC). 
Antigens, DCs and other lymphocytes migrating to the lymph node via the afferent 
lymphatics drain into the lymph node subcapsular sinus (SCS), which is lined by 
lymphatic endothelial cells (LEC). LECs regulate the entry of immune cells into 
and out of the lymph node. After naïve lymphocytes have searched for their 
cognate antigens, they leave the lymph node through the medullary sinus, also 
lined by LECs, and enter the efferent lymphatics. (von Andrian and Mempel, 2003; 
Girard et al., 2012; Miyasaka and Tanaka, 2004) 
LEC-regulated cell migration has been studied, yet the differences between the 
afferent and efferent lymphatics of the lymph node have not been thoroughly 
described. My doctoral studies set out to study the molecular differences between 
the LECs of the SCS and lymphatic sinus of the lymph node, representing the 
Introduction 
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afferent and efferent arm of the lymphatics, respectively. The cells were subjected 
to a genome-wide microarray to reveal molecular differences. Two molecules were 
selected for functional studies; namely, macrophage scavenger receptor 1 (Msr1) 
and magic roundabout (Robo4). Msr1 was shown to be expressed by the SCS 
LECs, and we discovered it to regulate lymphocyte migration via the lymphatics 
into the peripheral lymph node. Robo4 was discovered to be expressed by LECs of 
the medullary sinus as well as in the lymphatics of Peyer’s patches. We were able 
to describe a function for Robo4 in retaining a subset of naïve B cells in the Peyer’s 
patch suggesting a role for Robo4 in B cell turnover.  
Our studies also revealed a new mechanism for the filtering function of the 
lymph node. We discovered that large lymph-borne antigens and antibodies get 
instant access into the lymph node. Our studies indicate that LECs are the cell type 
actively transporting antibodies and other large antigens from the SCS into the 
lymph node parenchyma. This transport could be harnessed for immunomodulation 
of the immune response. The presented study reveals new mechanisms for LECs in 
regulating immune cell migration as well as antigen transport, both of which are 
fundamental for the successful function of our immune system. 
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2 Review of the Literature 
2.1 The lymphatic system 
The lymphatic system is a linear, open-ended network of lymphatic vessels 
connecting lymphoid organs to each other. In addition to lymphatic vessels, the 
lymphatic system comprises of the following organs: lymph nodes, the thymus, 
tonsils, spleen and Peyer’s patches. Protein-rich filtrate of plasma leaks out of the 
capillaries into the surrounding interstitium, where lymphatic capillaries absorb it 
creating lymph. Lymph is transported within the lymphatic vessels through lymph 
nodes and eventually to the thoracic duct, which connects to the subclavian vein. 
This one-directional movement of lymph ensures the careful filtering of its content 
by lymph nodes and the returning of extracellular fluid back to the bloodstream. 
Key functions of the lymphatic system are the uptake and recirculation of 
extracellular fluid as well as immune cells to lymphoid organs. Impairment in the 
recirculation of fluid leads to lymphedema, one of the main pathologies of the 
lymphatic system. The lymphatic system is also associated with other major 
pathologies such as atherosclerosis and cancer. (Choi et al., 2012; Moore Jr. and 
Bertram, 2018; Randolph et al., 2017)  
2.1.1 Early development of lymphatic vessels 
The lymphatic system develops independently of the blood vasculature. LECs can 
form by budding from existing veins, or they may differentiate from mesechymal-
cell derived precursors. (Ulvmar and Mäkinen, 2016) Around embryonic day (E) 
9.5, the prospero homeobox protein 1 encoding gene Prox1 is expressed by a 
subpopulation of vascular endothelial cells in the cardinal vein, which commits 
these cells to the lymphatic lineage and leads to the formation of early lymph sacs. 
The whole lymphatic system gradually develops from these primitive sacs. Mice 
lacking Prox1 completely fail to develop a lymphatic system as LEC budding from 
the cardinal vein is prematurely arrested. (Wigle and Oliver, 1999; Wigle et al., 
2002) Lineage studies with Prox1 reporter mice have confirmed the venous origin 
of LECs (Srinivasan et al., 2007). Expression of Prox1 is regulated by at least two 
other transcription factors: Sox18 and the orpan nuclear receptor Coup-TFII 
Review of the Literature 
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(chicken ovalbumin transcription factor II). Both of the transcription factors can 
directly activate Prox1, regulate its expression and thus contribute to committing 
cells to the lymphatic lineage. (François et al., 2008; Srinivasan et al., 2010) 
Although Prox1 has been termed the master regulator for lymphatic 
development, other molecules are also essential in the process. Vascular 
Endothelial Growth Receptor 3 (VEGFR-3) is expressed in lymphatic vessels 
during development (Kaipainen et al., 1995), and signaling through this receptor is 
required for the development and maintenance of the lymphatic vascular system 
(Mäkinen et al., 2001). One of its ligands, Vascular Endothelial Growth Factor C 
(VEGF-C), is expressed as early on as E8.5 in the region, where the first lymph 
sacs form. VEGF-C is required for the sprouting of Prox1-expressing LECs from 
the cardinal vein allowing them to produce the primitive lymph sacs. (Karkkainen 
et al., 2004) 
Lymphatics may also develop from non-endothelial cells. A subpopulation of 
dermal lymphatics was shown to have a non-venous origin, as skin lymphatics 
were visible after depletion of the blood vasculature (Martinez-Corral et al., 2015). 
Also, progenitor cells of the hemogenic endothelium, i.e. endothelial cells in the 
vascular endothelium that can differentiate into hematopoietic cells, proved to be 
the source for part of the mesenteric lymphatic vessels (Stanczuk et al., 2015) as 
well as a subset of cardiac lymphatics (Klotz et al., 2015). These studies, which 
concentrated on organ-specific lymphatics, confirm that lymphatics may develop 
from several different origins. 
2.1.2 Lymphatic vessel structure 
In the periphery, lymphatic vessels start out as capillaries or initial lymphatics 
designed for the uptake of fluids. Gradually the small capillaries form larger 
collecting vessels in a tree-like structure. The larger vessels are responsible for the 
transport of lymph and cells to the blood circulation. The collecting lymphatics 
finally merge into the thoracic duct, which drains lymph back into the blood 
circulation at the subclavian vein. (Randolph et al., 2005) 
Structurally, the initial lymphatics are thin, blind-ended vessels that are 
composed of a single endothelial cell layer. Unlike blood vessel capillaries, initial 
lymphatics have a discontinuous basement membrane and no surrounding pericytes 
or smooth muscle cells. Therefore, lymphatic capillaries connect to the 
extracellular matrix (ECM) with anchoring filaments. (Leak and Burke, 1968; 
Paupert et al., 2011) Endothelial cells of initial lymphatics are interconnected by 
special button-like junctions, which allows fluids to flow into the capillaries (Baluk 
et al., 2007). The initial lymphatics grow into precollector vessels surrounded by a 
poorly defined basement membrane, and these vessels further progress into the 
Ruth Fair-Mäkelä 
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collecting lymphatics. In comparison to the initial lymphatics, collecting 
lymphatics are surrounded by a basement membrane, pericytes and smooth muscle 
cells, and they exhibit continuous zipper-like junctions between endothelial cells. 
In addition, several lymphatic valves are present in precollecting and collecting 
lymphatics to aid fluid flow. (Baluk et al., 2007; Ryan, 1989) 
2.1.2.1 Lymphatic endothelial cells 
LECs line the lumen of lymphatic vessels similar to blood vessel endothelial cells 
(BEC) lining the lumen of blood vessels. LECs resemble BECs in several ways, 
and only research in the late 1990s discovered several lymphatic markers allowing 
studies to concentrate on the lymphatics. The differences between LECs and BECs 
as well as differences between the lymphatic and blood vasculature have been 
summarized in Table 1 and will be further discussed here. 
One of the early markers discovered for LECs was VEGFR-3 (Kaipainen et al., 
1995), which binds VEGF-C and VEGF-D (Achen et al., 1998; Joukov et al., 
1996). Around the same time, expression of LYVE1 (lymphatic vessel endothelial 
hyaluronan receptor 1, Banerji et al., 1999) and podoplanin (Breiteneder-Geleff et 
al., 1999) was reported to be specific for the lymphatics. Prox1 was discovered to 
regulate the lymphatic lineage in developmental studies (Wigle and Oliver, 1999). 
It has been shown to activate other lymphatic genes, such as VEGFR-3, and to 
downregulate genes associated with the blood vasculature when expressed in 
human cell lines. Thus, Prox1 has rightfully earned its title as master regulator. 
(Hong et al., 2002; Petrova et al., 2002) Neuropilin-2, a member of the non-kinase 
neuropilin receptors, is also expressed by the lymphatics, where it is important for 
the development of small lymphatic vessels and capillaries (Yuan et al., 2002). 
As most LECs are derived from the same origin as BECs, there are several 
common markers that are shared by the two vasculatures. Platelet endothelial cell 
adhesion molecule (PECAM-1, CD31) and VE-cadherin, both expressed in tight 
junctions connecting endothelial cells to each other, are known to be expressed by 
both vasculatures. (Ulvmar and Mäkinen, 2016) PLVAP (Plasmalemma vesicle 
associated protein), the antigen for the antibody PAL-E and MECA-32, also 
stained LECs in the lymph node in addition to its strong staining on blood vessels 
(Hallmann et al., 1995; Rantakari et al., 2015). Moreover, other molecules such as 
Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) 
and CD73 are expressed in both vasculatures variably in different tissues (Ålgars et 
al., 2011; Irjala et al., 2003). 
Despite being similar in many ways, LECs and BECs differ significantly in 
their energy metabolism. Although BECs are in direct contact with the oxygen they 
transport, they generate ATP via glycolysis, which is crucial for the rapid 
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expansion of endothelial cells in vitro (Parra-Bonilla et al., 2010). Defects in the 
glycolysis pathway also have an impact on BEC migration resulting in impaired 
blood vessel sprouting (De Bock et al., 2013). In contrast, LEC energy metabolism 
relies on fatty acid oxidation, which regulates LEC proliferation and differentiation 
by the direct binding of Prox1 to CPT1A, a rate-controlling enzyme of fatty acid 
oxidation (Wong et al., 2017). 
Table 1. Summary of the features of the lymphatic and blood vasculature and their significant 
differences as discussed in the text. 
  LYMPHATIC VASCULATURE BLOOD VASCULATURE 
MARKERS VEGFR-3, Prox1, LYVE1, 
podoplanin, PECAM-1, PLVAP, 
VE-cadherin 
PECAM-1, PLVAP, VE-
cadherin 
JUNCTIONS Button-like, zipper Zipper 
METABOLISM Fatty acid oxidation Glycolysis 
VESSEL SUPPORTING 
STRUCTURES 
Initial lymphatics: anchoring 
filaments 
Collecting lymphatics: basement 
membrane, pericytes, smooth 
muscle cells 
Basement membrane, 
pericytes, smooth muscle 
cells 
FUNCTION Maintaining fluid homeostasis, 
conveying immune cell migration, 
lipid uptake, nutrient transport 
Delivery of oxygen, nutrients, 
waste; transport of immune 
cells, barrier function 
MIGRATING IMMUNE 
CELLS 
Dendritic cells, effector and 
memory lymphocytes, 
macrophages 
All leukocytes 
2.1.3 Function of the lymphatic system 
Lymphatic vessels are present in nearly all tissues throughout the whole body. The 
lymphatic system has three major roles under homeostatic conditions: (1) 
maintaining interstitial fluid balance, (2) conveying antigen and immune cell 
trafficking throughout the body and (3) absorbing lipids and nutrients in the 
intestine. (Choi et al., 2012) The role of the lymphatics in antigen and immune cell 
migration will be described in detail under sections 2.2.3 and 2.3. 
2.1.3.1 Regulation of fluid homeostasis 
A protein-rich filtrate of plasma leaks out of blood vessel capillaries into the 
surrounding tissue. Lymph is produced when the interstitial pressure exceeds the 
pressure of the initial lymphatics forcing the protein-rich fluid from the tissue into 
the lymphatic vessels. Increased interstitial pressure causes tension, which results 
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in opening of the button-like junctions of the initial lymphatics. This allows fluid to 
flow into the vessel. After the interstitial fluid enters the initial lymphatic vessels, 
the pressure dynamics shift, and the greater pressure in the lymphatic vessel leads 
to the closing of the endothelial cell flaps. This in turn prevents the fluid from 
flowing back into the surrounding tissue. (Sabine et al., 2016; Zawieja, 2009) 
Low pressure in the peripheral lymphatics does not support the ’flowing’ of 
lymph towards the bloodstream. Instead, lymph is actively pumped along the 
vessels. As the interstitial pressure is close to or even lower than the atmospheric 
pressure, a pressure gradient favoring the production of lymph must be formed by 
the tissue or the lymphatic vessel itself. Extrinsic factors, such as muscle 
contraction and breathing, in addition to intrinsic factors, e.g. the contraction of the 
lymphatic vessel itself, aid the flow of lymph. The same factors are responsible for 
transporting the fluid throughout the lymphatic network up to the thoracic duct. 
(Schulte-Merker et al., 2011; Zawieja, 2009) 
Collecting vessels are surrounded by contracting smooth muscle cells and are 
divided into small functional units called lymphangions that are separated by 
valves. When lymph is transported into collecting vessels, it forms a pressure 
gradient that opens the valves downstream allowing lymph to flow forward, and 
simultaneously closes upstream valves preventing the backflow of lymph. In 
addition, contracting smooth muscle cells ensure the directional flow of lymph 
along the lymphatic network towards the bloodstream. (Morfoisse and Noel, 2019; 
Zawieja, 2009) 
2.1.3.2 Lipid absorption 
Lipids are absorbed by lymphatic capillaries in the small intestine villi i.e. lacteals. 
In contrast to initial lymphatics in the periphery, lacteals contain button-like and 
zipper juctions and they are found in close relation to contracting smooth muscle 
cells of the intestinal lamina propria. Lipid molecules are first absorbed by 
intestinal epithelial cells, which release them as mature chylomicrons that are 
actively taken up by lacteals. Chylomicrons are transported from lacteals to the 
collecting mesenteric lymphatic vessels and further to the systemic circulation. The 
flow of the intestinal lymphatic vessel content is ensured by contraction of the 
smooth muscle cells surrounding the lacteals, gut movement and contraction of the 
collecting mesenteric lymphatic vessels. Other molecules, such as fat-soluble 
vitamins and gut hormones, also get access to the lymphatics in chylomicrons. 
Albeit being one of the main functions of the lymphatic system, much remains to 
be discovered about the underlying mechanisms of lipid absorption and transport 
by the lymphatics. (Bernier-Latmani and Petrova, 2017; Hokkanen et al., 2019) 
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2.1.4 The lymphatic system in disease 
2.1.4.1 Abnormal fluid homeostasis 
The main function of the lymphatic system is to regulate tissue fluid homeostasis, 
which if impaired, leads to lymphedema. Lymphedema is distinguished by an 
increase in protein-rich fluid in the tissue leading to the swelling of extremeties, fat 
accumulation, fibrosis and other symptoms. This largely disabilitating condition 
can be primary or secondary. Primary lymphedema is a rare, hereditary condition 
and it is related to defects in lymphatic development as well as impaired valve 
function. In the Western world, secondary lymphedema is most often a result of 
radiotherapy or surgery used to treat breast cancer. In tropical countries, secondary 
lymphedema often results from lymphatic filariasis, a parasitic infection. 
Lymphedema can only be treated palliatively as no curative treatment exists. 
(Cueni and Detmar, 2008) 
2.1.4.2 Role in cancer 
A majority of solid tumors disseminate through the lymphatic system and form 
metastases in the sentinel or more distant lymph nodes. Lymph node metastases are 
regarded as a prognostic factor, which is often associated with reduced patient 
survival. The formation of metastases via the lymphatics is an actively regulated 
process. It starts with an increase of peritumoral lymphatics followed by cancer cell 
dissemination into the lymphatic vessels, and finally, the entry of tumor cells into 
the lymph node. Peritumoral lymphangiogenesis can be initiated by tumor-derived 
factors that also prepare the sentinel lymph node for metastases. Lymph node LECs 
have been shown to secrete factors that attract tumor cells into the lymph node. 
Therapeutic advances in this field are necessary for more effective patient care. 
(Alitalo and Detmar, 2012; Padera et al., 2016) 
2.2 The lymph node 
There are several hundreds of lymph nodes in humans that are situated 
strategically around the body in its periphery, in close vicinity to internal organs 
and the gut. Lymph nodes are connected by lymphatic vessels and are assembled 
in chains. Lymphatic vessels leading to the lymph node are called afferent 
lymphatics and vessels leaving the node are the efferent lymphatic vessels. 
Lymph nodes are the main organs that filter lymph. Depending on their 
anatomical location, lymph nodes encounter very different lymph-borne 
molecules. The main immunological function of the lymph node is to provide the 
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settings for initiating adaptive immune responses against foreign antigens 
delivered in lymph or transported within antigen-presenting DCs that migrate to 
draining lymph nodes. In addition to recognizing foreign antigens, the lymph 
node harbors cells important for the maintenance of tolerance against the host 
itself. (Girard et al., 2012) 
2.2.1 Lymph node organogenesis 
During embryonic development in the mouse, primitive lymph sacs rise at sites of 
major vascular junctions from E10.5 onward, which then develop into the early 
lymph node anlagen around E13. The main cells involved in lymph node 
organogenesis are lymphoid tissue inducer (LTi) cells of hematopoietic origin, and 
lymphoid tissue organizer (LTo) cells, which derive from mesenchymal cells. 
These cells interact via signaling of lymphotoxin-β receptor (LTβR) and its ligand 
lymphotoxin-α1β2 (LTα1β2). Other crucial signaling molecules include interleukin-7 
(IL-7) and the RANK-RANKL pathway. (Mebius, 2003; van de Pavert and 
Mebius, 2010) 
LTi cells rise from the fetal liver (Mebius et al., 2001), are the first cells to 
enter the developing lymph node anlagen (Mebius et al., 1997), and express 
many molecules essential for lymph node development, such as LTα1β2 (Mebius, 
2003). Cytokines, namely receptor activator of nuclear κ B (RANK) and IL-7 can 
further induce LTα1β2 expression in LTi cells (Yoshida et al., 2002). The early 
lymph node anlagen also harbors immature stromal cells expressing several 
adhesion molecules, which mediate the binding of LTi cells to the stroma. This 
allows LTβR to interact with its ligand resulting in the maturation of stromal 
cells into functional LTo cells. (Bénézech et al., 2010) As new LTi cells arrive to 
the anlagen, they upregulate LTα1β2 due to signaling via LTβR, which provides a 
positive feedback loop regulated by LTo cells. (Cupedo et al., 2004; Vondenhoff 
et al., 2009) 
LTi cell interaction with LTo cells triggers lymphotoxin signaling and leads 
to clustering of the LTi cells. This is contingent on adhesion molecules expressed 
by LTo cells, as well as chemokines that attract new LTi cells to the anlagen. The 
chemokine CXCL13 is important for the formation of lymph nodes, as mice 
lacking it fail to develop many peripheral lymph nodes. (Ansel et al., 2000) Other 
chemokines and chemokine receptors, such as CCL19, CCL21, CCR7 and 
CXCR5, also play a role in lymph node development (Luther et al., 2003; Ohl et 
al., 2003). Chemokines attract new LTi cells to the lymph node anlagen 
contributing to the established positive feedback loop between LTi and LTo cells. 
Neuron-derived factors have been suggested to induce expression of CXCL13 in 
the mesenchymal stromal cells of the anlagen. Indeed, CXCL13 has a major role 
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in attracting the first LTi cells to the anlagen, and therefore, factors inducing its 
expression take part in the early formation of the lymph node. (Van De Pavert et 
al., 2009) 
A long-prevailing concept was that LTo cells derive solely from a 
mesenchymal origin and regulate lymph node development via LTβR-signaling. 
However, lymph nodes develop even when LTβR-signaling in LTo cells is 
abrogated, suggesting that other regulatory cells exist. (Chai et al., 2013) If the 
LTβR coding gene Ltbr is depleted from LECs, the development of a substantial 
portion of lymph nodes is blocked, suggesting that LECs can also act as LTo cells 
(Onder et al., 2013). In fact, LECs are able to retain LTi cells in the lymph node 
anlagen providing the initial step for successful lymph node formation (Onder et 
al., 2017), as early blood vessels cannot support the CXCL13-induced recruitment 
of LTi cells to the anlagen (Onder and Ludewig, 2018). LECs are also needed for 
creating a CCL21 gradient to attract LTi cells (Onder et al., 2017) that can exit 
venules and enter the developing lymph node (Bovay et al., 2018). 
After the lymph node anlagen has developed, the lymph node goes under 
structural remodeling. The lymphatic and vascular infrastructure expands to 
facilitate the incoming lymphocytes starting at E18. In addition, the stromal cell 
compartment develops to support the hierarchical structure of the hematopoietic 
cells in the lymph node. The compartmentalized lymph node architecture is further 
defined by several factors resulting in a highly developed, central organ of the 
immune system. (Onder and Ludewig, 2018; Randall et al., 2008) 
2.2.2 Lymph node structure 
The lymph node is a compartmentalized organ divided into several structural 
regions. Surrounded by a fibrous capsule, the lymph node is comprised of the SCS, 
cortex, paracortex and medullary sinus (Figure 1). The major cells populating the 
lymph node are immune cells that are involved in recognizing foreign antigens and 
mounting corresponding immune responses. Stromal cells, including LECs, BECs 
and fibroblastic reticular cells (FRC) represent a small percentage of the total 
lymph node cells, yet they are indispensable for the function of the lymph node. 
Each region of the lymph node harbors a different set of immune and stromal cells 
with its own distinct functions. (Mueller and Germain, 2009) 
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Figure 1.  A schematic presentation of the lymph node structure showing the main cellular and 
structural components related to this thesis. The lymph node can be divided into the 
cortex, paracortex and the medullary sinus regions. Close-up images highlight the 
subcapsular sinus (SCS) showing the location of important stromal cells, the conduit 
network present in T cell zone as well as the medullary sinus. FDC, follicular dendritic 
cell, FRC fibroblastic reticular cell, HEV high-endothelial venule, IFR, interfollicular 
region, MRC marginal reticular cell, LEC lymphatic endothelial cell. 
2.2.2.1 Lymph node lymphatics 
LECs can be found in the SCS, cortical and medullary sinuses of the lymph node. 
Afferent lymphatic vessels leading to the lymph node penetrate its capsule and 
open up into the SCS. This hollow space under the capsule is lined by LECs that 
form the ceiling and floor of the sinus. Unlike LECs in the periphery, lymph node 
LECs have different expression patterns of lymphatic markers. LECs in the ceiling 
and floor both express Prox1 and VEGFR-3, but the ceiling can be distinguished by 
expression of the chemokine CCL1, chemokine receptor CCRL1 and podoplanin, 
whereas LECs in the SCS floor are positive for LYVE1 and CCL21. (Das et al., 
2013; Qu et al., 2004; Ulvmar et al., 2014) Lymph node LECs also express PLVAP 
in a distinct set of cartwheel-like subcellular structures called diaphragms, where it 
regulates endothelial permeability (Rantakari et al., 2015). LECs take part in 
regulating lymphocyte survival by producing several survival factors, such as IL-7 
(Malhotra et al., 2012). 
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In the lymph node, LECs are also present in the cortical sinuses that span the 
paracortex of the lymph node being the site where lymphocyte egress is initiated. 
Cortical sinuses attach to the medullary sinus leading to the efferent lymphatic 
vessels, the final exit route for lymphocytes. (Girard et al., 2012) The medullary 
sinus harbors medullary cords, where plasmablasts migrate to mature during 
humoral immune responses (Luther et al., 1997). These cords contain a blood 
vessel and are surrounded by LECs that separate the medullary cord content and 
blood vessel from the medullary sinus (Huang et al., 2018; Pfeiffer et al., 2008). 
The heterogeneity of lymph node LECs has recently gained interest, as 
techniques to study it have become availabe. Using microscopic analyses, LECs of 
the human lymph node were first divided into two subpopulations based on 
expression of LYVE1 and Stabilin-2 in the paracortical and medullary sinuses, and 
their absence in the SCS (Park et al., 2014). Using single-cell RNA sequencing, a 
more sophisticated and informative technique, Takeda and coworkers identified six 
different populations of LECs in the human lymph node. This suggests that LECs 
have distinct functions related to their location in the lymph node, which remain 
yet to be fully described. (Takeda et al., 2019) 
2.2.2.2 Lymph node blood vasculature 
The lymph node blood vasculature consists of arterioles, capillaries, unique post-
capillary venules termed high endothelial venules (HEV) and venules, all lined by 
BECs. Blood vessels enter and exit the lymph node at the hilus area near the 
efferent vessels, and they circulate throughout the whole lymph node. Capillaries 
provide oxygen and nutrients to the lymph node and convey migrating immune 
cells that exit the blood vasculature from HEVs. (Girard et al., 2012; Kowala and 
Schoefl, 1986) Endothelial cells of capillaries and HEVs differ significantly in their 
gene expression reflecting their clear functional differences. Whereas capillary 
endothelial cells express genes related to vascular development, endothelial 
differentiation and fluid transport, HEV-expressed genes are related to lymphocyte 
migration, inflammatory response and lymph node development. (Lee et al., 2014) 
HEVs have a distinct morphology that is not found in other venules. Their 
endothelial cells are plump and cuboidal, the venules are surrounded by a thin basal 
lamina further ensheathed by FRCs with collagen-containing bundles, and they are 
wrapped by surrounding pericytes. (Anderson et al., 1976; Freemont and Jones, 
1983) 
HEVs are the prominent exit site for lymphocytes entering the lymph node 
parenchyma. They also harbor lymphocytes waiting for entry in ’pockets’ between 
the endothelial cells and the surrounding stroma. The constant presence of 
lymphocytes contributes to the morphology of HEVs, as in the absence of 
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lymphocytes they become flattened. (Mionnet et al., 2011) Lymph node HEVs are 
best distinguished from other vascular endothelial cells by their expression of the 
MECA-79 antibody epitope, peripheral node addressins (PNAd), which are vital 
for lymphocyte migration (Streeter et al., 1988). In addition, HEVs express several 
other molecules involved in lymphocyte migration that are further discussed in 
section 2.3.2. 
Single-cell sequencing reveals endothelial cells in HEVs to be a heterogeneous 
cell population exhibiting spatial differences in the expression of molecules 
important for lymphocyte migration (Veerman et al., 2019). Interestingly, DCs 
regulate the HEV phenotype by maintaining their mature phenotype. If DCs are 
depleted from the lymph node, HEVs dedifferentiate into an immature state, which 
reduces lymphocyte migration into the lymph node. DCs express the ligand for 
HEV-expressed LTβR, and this signaling is required for the mature phenotype of 
HEVs and successful lymphocyte migration. (Moussion and Girard, 2011) In 
addition to DCs, FRCs also regulate HEVs via LTβR regulated expression of 
VEGF, which is needed for the proliferation and maintenance of the blood 
vasculature (Chyou et al., 2008). 
2.2.2.3 Reticular cells of the lymph node 
A major cell population of the lymph node stromal cell compartment is the 
mesenchymal cell derived reticular cell population. These cells are characterized as 
podoplanin+ and are negative for CD31 and CD45 separating them from 
endothelial and hematopoietic cells, respectively. A majority of reticular cells are 
FRCs, but the population also contains marginal reticular cells (MRC) found in the 
SCS, follicular dendritic cells (FDC) supporting B cell follicles and other 
specialized podoplanin+ stromal cells. Stromal cells also contain a ’double 
negative’ population negative for both podoplanin and CD31. (Malhotra et al., 
2013) 
2.2.2.3.1 Fibroblastic reticular cells 
FRCs produce a reticular network that spans throughout the lymph node and is 
most prominent in the T cell zone of the paracortex. The reticular network, also 
termed the conduit system, is ensheathed by FRCs that produce the ECM of the 
conduit. The conduit core consists of collagen I fibres that are surrounded by an 
ER-TR7+ microfibrillar zone, a basement membrane and finally the FRC itself. 
(Kaldjian et al., 2001; Sixt et al., 2005) The reticular network offers structural 
support and elasticity for the lymph node and regulates the spatial regionality of 
lymphocytes by guiding their migration. Moreover, the conduit network regulates 
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the size-selective entry of antigens into the lymph node contributing to the lymph 
node filtering function. (Mueller and Germain, 2009) 
FRCs span the whole lymph node from the SCS to the medullary sinus. Based 
on single-cell sequencing, FRCs can be divided into nine distinct populations 
located in different regions of the lymph node. In addition to the T cell zone, 
independent FRC populations were identified in the interfollicular (IFR) regions of 
the cortex, at the interface of follicles and the T cell zone, in the perivascular 
region, and finally in the medullary sinus. (Rodda et al., 2018) Transcriptional 
analyses define the ’double negative’ population of FRCs as contractile, pericyte-
like cells located around vessels and in the medullary sinus (Malhotra et al., 2012). 
FRCs regulate the intranodal migration of newly entering lymphocytes by 
expressing CCL19 and CCL21, ligands of CCR7 (Bajénoff et al., 2006a). FRCs 
also support naïve T cell survival by expressing IL-7 and CCL19 (Link et al., 2007) 
in addition to supporting B cell survival by secreting the B cell activating factor, 
BAFF. When FRCs are depleted from the lymph node, its cortex and B cell 
follicles lose their structural integrity and B cells fail to conduct proper humoral 
responses. (Cremasco et al., 2014) Moreover, specialized medullary reticular cells 
present in medullary cords are important for the regulation of plasmacell 
homeostasis through the secretion of survival factors (Huang et al., 2018). 
2.2.2.3.2 Follicular stromal cells 
The main stromal cells present in the lymph node B cell follicles are FDCs, which 
secrete CXCL13 attracting and retaining B cells in the follicles (Cyster et al., 
2000). Depleting FDCs disrupts the separation of the T cell zone and B cell 
follicles (Wang et al., 2011). When B cells go under activation, germinal centers 
(GC) arise within follicles. GCs can be divided into dark and light zones based on 
the supporting stromal cells. FDCs are present in the light zone, whereas CXCL12-
secreting reticular cells colonize the dark zone that contains proliferating B cells. 
(Rodda et al., 2015) 
MRCs are a distinct stromal cell population present in the SCS at the top of B 
cell follicles. They can be distinguished from other podoplanin+ stromal cells by 
expression of mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) 
and RANKL. (Katakai et al., 2008) Similar to FDCs, MRCs secrete CXCL13 
attracting B cells to follicles, where they can also present antigens to B cells 
(Katakai, 2012). MRCs are also known to create a niche supporting innate 
lymphoid cells in the SCS (Hoorweg et al., 2015). 
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2.2.2.4 Lymph node immune cells 
2.2.2.4.1 Lymphocytes 
Immune cells mainly reside in the cortex and paracortex areas of the lymph node. 
Naïve B cells form follicles in the cortex, where B cell responses take place. Upon 
antigen recognition, B cells are activated and can differentiate into plasmablasts, 
which are able to rapidly produce antibodies. Alternatively, B cells enter GCs 
within the follicles containing mitotic B cells. In GCs, B cells undergo affinity 
maturation resulting in their differentiation into specific antibody secreting plasma 
cells, some of which stay in the lymph node whereas others migrate to the bone 
marrow. (Batista and Harwood, 2009) Antigens are presented to B cells by several 
different cell types discussed later. Naïve B cells enter the lymph node via HEVs in 
the paracortex and migrate to the cortex following a CXCL13 chemokine gradient 
secreted by FDCs. (Girard et al., 2012) A low number of NK cells, which develop 
from the same progenitors as lymphocytes, are present in the lymph node during 
steady state. They reside at the border between follicles and T cells as well as in the 
medullary sinus. (Bajénoff et al., 2006b; Garrod et al., 2007) 
CD4+ and CD8+ T cells are retained in the paracortex by chemokine signals that 
guide their entry and intranodal migration. They express the chemokine receptor 
CCR7, which responds to its ligands CCL19 and CCL21 expressed by FRCs. 
Antigen-presenting DCs also reside in the paracortex, which increases the 
likeliness of a naïve T cell to encounter its cognate antigen presented by a DC. 
(Girard et al., 2012) After encountering antigens, CD4+ T cells mature into effector 
cells of different subtypes such as Th1, Th2, Th17, T follicular helper cells (Tfh) 
and induced T regulatory cells (Treg), depending on the activating stimuli. These 
cells migrate into different regions of the lymph node in a CXCR3-dependent 
manner, where antigen encounter is highly probable, such as the IFR of the cortex 
and the medullary sinus. IFRs receive a large load of antigens within DCs 
migrating from the periphery or directly from the SCS, and they are sites for direct 
priming of T cells in addition to harboring memory cells. (Groom, 2019; Groom et 
al., 2012) 
2.2.2.4.2 Resident macrophages 
Lymph node macrophages are mainly located within its sinuses, where they are in 
direct contact with the antigen-rich lymph. These macrophages can be divided into 
four populations: subcapsular sinus macrophages (SSM, CD169+ F4/80–), 
medullary sinus macrophages (MSM, CD169+ F4/80+), medullary cord 
macrophages (MCM, CD169– F4/80+) and paracortical macrophages (CD68+) that 
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possibly overlap with T cell zone marcophages (CX3CR1hi CD64+ MERTK+). 
(Baratin et al., 2017; Gasteiger et al., 2016) SSM line the SCS floor by sitting 
beneath the endothelial cell layer. These macrophages extend a part of their cell 
body into the SCS lumen while simultaneously reaching into B cell follicles with 
long cellular protrusions. This creates a web of several different cell types all 
intermingled in the SCS floor. SSM are poorly endocytic but they retain 
immunocomplexes on their surface for antigen presentation to B cells. (Phan et al., 
2007, 2009) MSM reside in the lymph node medulla and in regions between B cell 
follicles and the medullary sinus, where these highly phagocytic cells trap lymph-
borne antigens and take part in their clearance (Grigorova et al., 2009). T cell zone 
macrophages are located in the T cell region where they dispose of apoptotic cells 
(Baratin et al., 2017). 
The SCS is structurally intriguing as it harbors several different cell types that 
create a suitable niche for SSM survival. RANK is expressed by both MRC and 
LECs in the SCS, which is required for the survival for SSM and MSM. Moreover, 
LECs in the SCS and medullary sinus are the major cell type secreting colony 
stimulating factor 1 (CSF1), the master regulator of macrophage survival, which 
contributes to the maintenance of lymph node sinus macrophages. (Camara et al., 
2019; Mondor et al., 2019) 
2.2.2.4.3 Dendritic cells 
DCs are professional antigen presenting cells that are essential for the initiation of 
adaptive immune responses. In homeostatic conditions, DCs maintain tolerance by 
introducing self-molecules to T cells, whereas they transport antigens from the 
periphery to secondary lymphoid organs during inflammation. The lymph node 
harbors several types of DCs, both resident i.e. classical DCs (cDC) and migratory 
cells. At steady state, dermal DCs and Langerhans cells migrate from the skin to 
the lymph node via the lymphatics. Their migration is greatly increased during 
inflammation, when they actively present antigens to naïve T cells in the lymph 
node. The lymph node is largely populated by resident DCs that arrive via the 
blood vasculature. Resident DCs can be roughly divided into CD8α+ CD11b- cDC1 
or CD8α- CD11b+ cDC2 populations and plasmacytoid DCs. (Itano and Jenkins, 
2003; Randolph et al., 2008; Worbs et al., 2017) The deep T cell zone is 
predominantly occupied by cDC1 cells, which present antigens more efficiently to 
CD8+ T cells. In contrast, cDC2 cells populate areas proximal to lymphatic sinuses, 
where they activate CD4+ T cells. After migratory DCs arrive to the lymph node, 
they populate the lymph node in a mixed pattern. The regionality of resident DCs is 
reflected by the T cell proliferation they induce; as T cells proliferate in the 
locations they have been activated in. (Gerner et al., 2012, 2017) 
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2.2.3 Function of the lymph node 
 
Figure 2.  Antigens arriving to the lymph node are sorted based on their size allowing <70 kDa 
molecules to directly enter the conduit system. Large soluble antigens (>70 kDa) are 
excluded from the lymph node parenchyma, yet some are able to diffuse through gaps 
in the subcapsular sinus (SCS) floor over time. Resident subcapsular sinus 
macrophages (SSM) and dendritic cells (DC) phagocytose bacteria from the SCS and 
transport large soluble antigens to B cells, whereas virions are able to enter the 
conduit. LEC, lymphatic endothelial cell. 
2.2.3.1 Transporting antigens 
2.2.3.1.1 Role of the reticular conduit 
Lymph delivers antigens from the periphery to the lymph node, where they are 
sorted in the SCS based on their size. The conduit instantly delivers small soluble 
antigens with a size under 70 kDa from the SCS to the lymph node parenchyma 
and the luminal surface of HEVs. The size limit is a feature of the collagen core of 
the conduit, which physically only allows molecules with a hydrodynamic radius 
below 5-6 nm (equivalent to molecular weight <70 kDa for globular proteins) to 
enter the conduit (Figure 2). Large lymph-borne molecules, such as antibodies (size 
150 kDa) do not get access to the parenchyma and are instead concentrated in the 
SCS and medullary sinus, where they slowly begin to penetrate into the 
parenchyma. (Gerner et al., 2017; Gretz et al., 2000; Roozendaal et al., 2009; Sixt 
et al., 2005) The sorting of lymph-borne molecules in the SCS is orchestrated by 
PLVAP – a protein sieve in LECs that sits on top of the conduit openings 
performing size-selective sorting. In mice deficient of PLVAP, large antigens up to 
500 kDa have access to the conduit, which leads to increased uptake of antigens by 
macrophages and DCs in the lymph node parenchyma. (Rantakari et al., 2015) 
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The conduit system also transports fluids and endogenous soluble molecules in 
addition to foreign antigens. Large volumes of fluids flow within distinct conduits 
associated with the lymph node capsule that are comprised of elastin fibers (Lin et 
al., 2018). Chemokines are produced in the periphery during inflammation and are 
collected into draining lymph nodes. Here, chemokines enter the conduit and are 
delivered to the bloodstream through HEVs to recruit lymphocytes into the lymph 
node. (Gretz et al., 2000) Locally produced IgM in lymph nodes is taken up by the 
conduit and exported out of lymph nodes through the vasculature during immune 
responses. As pentameric IgM is a large molecule (size 900 kDa), it seems that the 
size-selective nature of the conduit is related to the SCS and in fact, large 
molecules are able to gain access to the conduit when already present in the lymph 
node parenchyma. (Thierry et al., 2018) 
2.2.3.1.2 Large antigens 
In the periphery, DCs phagocytose large antigens, such as microbes, and migrate 
into draining lymph nodes to present microbe-derived peptides to naïve T cells. 
Migratory DCs arrive to the lymph node in approximately 12 hours after 
inflammatory stimuli. However, some studies have shown DCs to ingest antigens 
in the draining lymph nodes before the arrival of migratory DCs. (Itano and 
Jenkins, 2003) FRCs cover about 90% of the conduit network and 60-80% of 
lymph node resident DCs are in direct contact with this network. These resident 
cells are able to sample and process soluble antigens directly from the conduit, and 
initiate immune responses before migratory DCs get access to the lymph node. 
(Sixt et al., 2005)  
Immunocomplexes, i.e. molecular complexes formed by the binding of 
antibodies to antigens, are taken up directly from the lymph by SSM in the SCS 
lumen. Follicular B cells capture these immunocomplexes from the elongated 
protrusions of the macrophages and deliver the antigens to FDCs in a complement 
receptor dependent manner. (Phan et al., 2007) Moreover, large experimental 
peptide:MHCII (major histocompatibility complex class II) complexes can slowly 
diffuse directly from the SCS to the interstitium surrounding parenchymal 
lymphocytes several minutes after being subcutaneously (s.c.) administered. 
Diffusion is thought to take place through small gaps in the SCS floor and it is 
independent of any receptor or the conduit system. (Gerner et al., 2017; Pape et al., 
2007; Roozendaal et al., 2009) In contrast, small immunocomplexes resemble 
small soluble antigens and get access to the lymph node by entering the reticular 
conduit present in B cell follicles (Roozendaal et al., 2009). 
Ruth Fair-Mäkelä 
 30 
2.2.3.1.3 Infectious agents 
Afferent lymphatics deliver pathogens from the periphery to draining lymph nodes, 
where different cells actively combat infection primarily in the lymph node sinuses. 
Several viruses can infect the poorly phagocytic SSM, which is critical in 
preventing systemic dissemination of the pathogen. These macrophages transfer 
viruses from the SCS to follicular B cells to initiate humoral immune responses. 
(Junt et al., 2007; Kastenmüller et al., 2012) In addition to macrophages, the SCS 
harbors a specialized population of resident DCs that also phagocytose bacteria 
from the SCS lumen and induce T cell activation (Gerner et al., 2015). Resident 
DCs in the lymph node medulla are also involved in the internalization of viruses, 
which subsequently induces DC migration towards FDCs followed by the initiation 
of a humoral immune response (Gonzalez et al., 2010). Surprisingly, despite being 
large, viruses are also able to enter the reticular conduit upon infection and infect 
paracortical DCs followed by T cell activation. The ability of viruses to enter the 
conduit is regulated by PLVAP, as its absence markedly increases the viral load of 
the conduits as well as the number of infected cells. (Reynoso et al., 2019) 
2.2.3.2 Stromal cells regulate peripheral tolerance 
Several lymph node stromal cells are able to present antigens and have a role in 
maintaining peripheral tolerance. Although DCs are the professional antigen 
presenting cells, stromal cells are also able to directly present antigens to T cells 
and induce their proliferation. However, as stromal cells lack costimulatory 
molecules, proliferating T cells are unable to excert effector functions and instead, 
they undergo deletion. (Hirosue and Dubrot, 2015) Lymph contains many self-
antigens, as it is concentrated with the proteins and peptides derived from the 
tissues it drains. Therefore, self-antigens are readily available for stromal cells in 
the lymph node, especially LECs that are directly in contact with the lymph in the 
SCS. (Clement et al., 2011)  
Peptides derived from intracellular antigens are presented on MHCI (major 
histocompatibility complex class I) molecules to cytotoxic CD8+ T cells. Stromal 
cells (FRC, LEC, BEC) express several peripheral tissue antigens often in distinct 
subpopulations, which they can present to CD8+ T cells leading to tolerance against 
these self-antigens. (Cohen et al., 2010; Fletcher et al., 2010; Hirosue and Dubrot, 
2015) LECs are also able to directly scavenge and internalize foreign antigens 
present in lymph and present them to CD8+ T cells that undergo activation. In 
contrast to DCs, LECs express high levels of the inhibitory molecule PD-L1 and 
cause upregulation of PD-1 and CTLA4 on lymphocytes. This dampens the 
activation of T cells resulting in the deletion of antigen specific T cells and 
maintenance of tolerance. Antigen presentation conducted by LECs is therefore 
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significant in regulating downstream effects and has a role in preventing 
autoimmunity. (Hirosue et al., 2014; Tewalt et al., 2012) 
In addition to expressing MHCI, lymph node stromal cells (FRC, LEC, BEC) 
express MHCII that is required for the presentation of extracellular antigens to 
CD4+ T cells (Malhotra et al., 2013). LECs are able to synthesize MHCII, or they 
can acquire it directly from DCs. Yet, LECs are unable to initiate CD4+ cell 
proliferation as they lack molecules of the antigen presentation machinery. 
However, DCs may acquire tissue antigen-derived peptides from LECs, present 
them to T cells and induce T cell anergy in the lymph node. Thereby, LECs act as a 
reservoir for tissue antigens and they can indirectly regulate T cell tolerance. 
(Rouhani et al., 2015) LECs and FRCs can also acquire peptide:MHCII complexes 
from DCs by direct cell-cell contact or within exosomes. In such case, they are able 
to directly promote CD4+ T cell apoptosis. (Dubrot et al., 2014) Stromal cells also 
maintain regulatory T cells in lymph nodes by presenting antigens directly to them 
via MHCII (Baptista et al., 2014). 
2.3 Immune cell migration 
Immune cells migrate into lymph nodes via two different routes: the afferent 
lymphatics and the blood circulation. The main cell populations migrating via the 
afferent lymphatics are CD4+ effector and memory T cells as well as DCs under 
homeostatic conditions (90% and 10% of afferent lymph cell composition, 
respectively). However, a low number of B cells, monocytes and granulocytes can 
also be detected in the afferent lymph. Naïve T cells mainly enter lymph nodes via 
HEVs of the blood vasculature in search of foreign antigens. If naïve T cells do not 
encounter their cognate antigens after 6-12 hours of scanning DCs in the lymph 
node, they will egress the lymph node via the efferent lymphatics. Subsequently, 
the cellular composition of lymph changes drastically after it flows through the 
lymph node resulting in efferent lymph being mainly composed of naïve 
lymphocytes that originally entered the lymph node through HEVs. (Hall and 
Morris, 1962; Hunter et al., 2016; Mackay et al., 1988; Smith et al., 1970) A 
schematic overview of immune cell migration described in detail hereafter is 
presented in Figure 3. Immune cell recirculation between lymph nodes and the 
blood circulation occurs in peaks, where cell entry into lymph nodes peaks at the 
onset of active time and egress is most active during the resting phase. The 
circadian rhythm of immune cell migration is controlled by clock-genes expressed 
in lymphocytes, which regulate the molecules that are mainly involved in 
migration. Adrenergic nerves can also regulate the circadian rhythm. In both cases, 
oscillations in cell migration affect adoptive immunity. (Druzd et al., 2017; Nakai 
et al., 2014) 
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Figure 3. A schematic view of immune cell migration into lymph nodes highlighting the most 
important molecular gradients regulating cell migration. Migratory dendritic cells 
(migDC) as well as effector and memory T cells (Eff/Mem T cell) are able to enter the 
initial lymphatics following local CCL21 gradients and migrate to the draining lymph 
node. Immune cells arriving among the lymph cross the subcapsular sinus (SCS) to 
enter the lymph node parenchyma following a CCL21 gradient, which is regulated by 
CCRL1-expressing lymphatic endothelial cells (LEC, 1). Naïve T and B lymphocytes 
migrate to lymph nodes in the bloodstream and enter the node via specialized high-
endothelial venules (HEV, 2). Lymphocytes migrate intranodally to their allocated 
locations guided by CCR7/CXCR5 and their ligands, which are produced by 
fibroblastic reticular cells (FRC, 3). Lymphocyte egress takes place at the cortical 
sinus, where lymphocytes follow a sphingosine-1-phosphate (S1P) gradient into the 
sinus and to the efferent lymphatics thereafter (4). 
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2.3.1 Migration via afferent lymphatics 
2.3.1.1 Intravasation into lymphatics 
Immune cells enter afferent lymphatics in peripheral tissues and migrate to the 
draining lymph node. The main molecules regulating DC migration via the afferent 
lymphatics are the chemokine receptor CCR7 expressed by DCs themselves, and 
its ligand, CCL21. DCs migrate towards the inital blunt-ended lymphatics attracted 
by a CCL21 gradient that is formed by the constant secretion of CCL21 by LECs. 
(Weber et al., 2013) Once DCs come into contact with the lymphatic vessel, they 
attach onto its abluminal side and cluster around pores of the basement membrane, 
where they actively push the basement membrane aside creating space for entry. 
(Pflicke and Sixt, 2009; Tal et al., 2011) DCs probe the abluminal surface of LECs 
with cellular extensions causing them to release a burst of CCL21 that accumulates 
at the endothelial cell junctions. DCs then migrate into the lymphatic vessel lumen 
through the flaps between endothelial cell tight junctions guided by the high local 
concentration of CCL21. (Vaahtomeri et al., 2017) In the vessel lumen, DCs crawl 
downstream along the lymphatic capillaries directed by an intraluminal CCL21 
gradient. Finally, DCs enter collecting lymphatic vessels, where they are passively 
transported to the draining lymph node by lymphatic flow. (Russo et al., 2016) 
Similar to DCs, T cell migration into skin lymphatics and the draining lymph 
node is dependent on CCR7 under steady state and acute inflammation. Although 
being a minor cell population in the afferent lymph, naïve T cells have also been 
observed in parenchymal tissues such as the skin and they are able to migrate into 
draining lymph nodes under experimental settings. (Cose et al., 2006; Debes et al., 
2005) During chronic inflammation, T cell intravasation into the initial lymphatics 
is CCR7-independent and is regulated by the ICAM-1/LFA-1 pathway instead. 
After entering the initial lymphatics, T cells actively crawl along the endothelium 
by adhering to LEC-expressed ICAM-1 (Intercellular Adhesion Molecule 1) until 
they reach the collecting lymphatics, where cells are transported passively to the 
draining lymph node among lymph. (Brown et al., 2010; Teijeira et al., 2017) 
While crawling in the lymphatics, T cells may interact with DCs allowing for T 
cell priming to begin already in the periphery (Hunter et al., 2019). Although 
integrins do not play a role in DC migration under steady state (Lämmermann et 
al., 2008), they regulate DC migration during chronic inflammation (Johnson et al., 
2006). 
Podoplanin and LYVE1 both have a role in regulating DC migration into the 
afferent lymphatics and draining lymph node. DCs express CLEC-2 (C-type lectin-
like receptor 2), the receptor for podoplanin, and their interaction is required for 
DCs to get access to the inital lymphatics (Acton et al., 2012). Similarly, the 
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binding of LYVE1 (expressed by the lymphatics) to its ligand hyaluronan 
(expressed on DCs) is important for DC adhesion to the lymphatics and their 
transmigration into the vessel (Johnson et al., 2017). Interestingly, the main 
regulators of lymphocyte egress from the lymph node, namely sphingosine-1-
phosphate (S1P) and its receptor S1P1 also play a role in regulating lymphocyte 
egress from peripheral tissues. The S1P–S1P1 pathway is mainly involved in the 
transmigration of T cells through the LEC layer causing retention of T cells in the 
tissue. (Ledgerwood et al., 2008; Xiong et al., 2019) Moreover, macrophage 
mannose receptor (CD206) and its ligand CD44 (Salmi et al., 2013), Clever-1 
(Karikoski et al., 2009) and CD73 (Ålgars et al., 2011) regulate lymphocyte 
migration to the draining lymph node via the afferent lymphatics. 
2.3.1.2 Migration through the SCS 
When arriving to the SCS lumen, cells in the afferent lymph need to cross the 
barrier of the SCS floor to gain access to the lymph node parenchyma. DCs migrate 
across the SCS floor and enter the lymph node at IFRs. DC migration is regulated 
by CCR7 and gradients of its ligand, CCL21 produced by FRCs in the parenchyma. 
These gradients are controlled by CCRL1, the atypical chemokine receptor 
expressed by LECs in the SCS ceiling. CCRL1 maintains a gradient by scavenging 
CCL21 at the opposing position from CCRL1 itself. As a result, the CCL21 
gradient is at its lowest right below the SCS floor and increases towards the center 
of the lymph node. Attracted towards the high concentrations of CCL21 further 
away in the lymph node parenchyma, DCs migrate through the SCS floor in a 
CCR7 dependent manner. (Braun et al., 2011; Ulvmar et al., 2014) Lymph-borne 
monocyte derived DCs use CCR8 to migrate into the draining lymph node. Its 
ligand, CCL1 is expressed by LECs of the SCS floor, where it regulates the entry 
of DCs into the parenchyma. (Qu et al., 2004) 
T cells injected directly into the afferent lymphatics flow passively to the 
medullary sinus and enter the lymph node from there. Lymphocytes first migrate 
into medullary cords, and thereafter cross the LYVE1+ LECs to enter the lymph 
node parenchyma. However, if T cells and DCs are administered at the same time, 
T cells will follow DCs in crossing the SCS floor at IFRs. (Braun et al., 2011) 
Similarly, activated T cells cross the SCS when entering the lymph node 
parenchyma. Crossing of the SCS is mediated by CCR7 as well as integrins. 
(Martens et al., 2020) Unlike DCs, T cells can be found in downstream lymph 
nodes suggesting that many of them pass through the chain of lymph nodes without 
even entering the lymph nodes (Braun et al., 2011). PLVAP, expressed by the SCS 
floor LECs, also regulates the entry of lymph-borne lymphocytes into the lymph 
node. If PLVAP is depleted, lymphocyte transmigration through the SCS is 
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increased. As PLVAP forms a physical sieve-like structure in LECs, its absence 
might allow lymphocytes to protrude the LEC layer more readily at points of low 
resistance leading to increased entry of lymphocytes to the lymph node. (Rantakari 
et al., 2015) Blocking PLVAP with an antibody results in diminished migration of 
lymphocytes into the lymph node, a discovery currently challenged by others 
(Martens et al., 2020; Rantakari et al., 2015). 
 
Figure 4.  A schematic representation of the homing of lymphocytes to the lymph node via high 
endothelial venules (HEV). Steps of the adhesion cascade, i.e. the tethering and 
rolling of lymphocytes, chemokine mediated activation, integrin mediated arrest, 
intraluminal crawling and transmigration have been illustrated. Figure adapted from 
Ley et al., 2007. 
2.3.2 Migration via the blood vasculature 
Naïve B and T cells are the most frequent cells entering the lymph node through 
the blood vasculature at specialized post-capillary venules, HEVs. During 
homeostatic conditions, other immune cells such as plasmacytoid DCs, precursory 
DCs and NK cells are also able to enter the lymph node via HEVs. Lymphocyte 
migration, often called ’homing’, to the lymph node occurs in a multistep adhesion 
cascade (Figure 4), which involves rolling, activation, adhesion, intraluminal 
crawling and transmigration of lymphocytes through HEVs. (von Andrian and 
Mempel, 2003; Butcher and Picker, 1996; Girard et al., 2012) 
The first contacts between naïve lymphocytes and the vascular endothelium 
take place under high blood flow. This tethering, which turns into lymphocytes 
rolling on the endothelium, is mediated by L-selectin (CD62L) expressed by 
lymphocytes and its ligand PNAd on HEVs. If blocked by antibodies against L-
selectin or PNAd (using the MECA79 antibody) lymphocyte adhesion to the 
endothelium and subsequent migration into lymph nodes is abrogated. (Berg et al., 
1991; Gallatin et al., 1983; Michie et al., 1993; Streeter et al., 1988) PNAd is 
comprised of several sialomucins (GlyCAM-1, CD34, endomucin, podogalyxin, 
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endoglycan, nepmucin) that are all recognized by MECA79. L-selectin binds to a 
specific carbohydrate determinant, namely 6-sulpho sialyl Lewis X present on 
PNAd and all of its other ligands. (Girard et al., 2012; Rosen, 2004) 
The rolling of lymphocytes on the endothelium slows them down and allows 
them to interact with HEV-bound chemokines to induce integrin activation. HEVs 
directly express CCL21 bound on heparan sulfate, which interacts with CCR7 
expressed on naïve lymphocytes and induces activation of LFA-1 (Lymphocyte 
Function-associated Antigen 1). (Bao et al., 2010; Gunn et al., 1998; Stein et al., 
2000; Warnock et al., 1998) In addition to CCL21, CCL19 and other chemokines 
can be transcytosed to the HEV lumen, where they can interact with the rolling 
lymphocytes (Baekkevold et al., 2001). Although CCR7 is the most prominent 
chemokine receptor involved in integrin activation, CXCR4 also plays a role in the 
activation of B cell integrins by binding to CXCL12 present on the lumen of HEVs 
(Okada et al., 2002). 
Activated LFA-1 on naïve lymphocytes binds tightly to ICAM-1 expressed on 
HEVs, which leads to the firm arrest of lymphocytes to the endothelium. By 
functionally blocking LFA-1, or in mice devoid of LFA-1, the interactions of 
lymphocytes with the endothelium are inhibited and lymphocyte migration to 
lymph nodes is dramatically impaired. (Andrew et al., 1998; Hamann et al., 1988) 
Interestingly, during the rolling of lymphocytes, their deceleration is not because of 
gradual activation of LFA-1 and subsequent binding of lymphocytes to the 
endothelium. Instead, LFA-1 activation requires triggering by immobilized 
chemokines. All of this takes place in seconds and results in an abrupt stop of the 
rolling lymphocyte at its site of extravasation. (Shamri et al., 2005) ICAM-1 plays 
a predominant role in lymphocyte arrest to the vascular endothelium, but to a lesser 
extent, ICAM-2 is involved in the adhesion of lymphocytes that do not adhere to 
ICAM-1. A small role has been discovered for α4 integrins, namely LPAM and 
VLA-4 (Very Late Antigen-4) on lymphocytes, and their ligand VCAM-1 
(Vascular Cell Adhesion Molecule 1) expressed on the luminal endothelium, in the 
migration of lymphocytes to lymph nodes. By acting together with LFA-1, α4 
integrins are able to regulate lymphocyte entry to lymph nodes in steady state. 
(Berlin-Rufenach et al., 1999; Boscacci et al., 2010) 
A majority of arrested lymphocytes extravasates the HEV at the site they attach 
to, but roughly a third of lymphocytes crawl along the endothelium before 
initiating transmigration across HEVs. Crawling can occur in the direction, against 
it or perpendicular to the blood flow for about 20 μm before cells initiate 
transmigration. (Boscacci et al., 2010) This type of migration is regulated by the 
LFA-1/ICAM-1 pathway, while α4 integrins play no role (Park et al., 2010; 
Shulman et al., 2009). For lymphocytes to successfully transmigrate through the 
endothelium, they initiate active migration while the endothelial cell undergoes 
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molecular changes. Lymphocytes respond to exit cues provided by chemotactic and 
haptotactic gradients created by the endothelial cells, ECM and other immune cells 
surrounding the blood vessel. The clustering of ICAM-1 and recruitment of 
VCAM-1 to the site of extravasation is also induced by lymphocyte arrest on the 
endothelium. Once the transmigrating cell has reached the endothelial cell junction, 
molecules regulating these junctions, such as VE-cadherin (vascular endothelial 
cadherin), are relocated to allow the migration of lymphocytes. Other junctional 
molecules such as the JAM (Junctional Adhesion Molecules) family and CD31 are 
also involved in lymphocyte transmigration. Most cell transmigration takes place 
between adjacent endothelial cells (paracellular) but in some cases, lymphocytes 
migrate through the endothelial cell body (transcellular migration). (Muller, 2016; 
Nourshargh and Alon, 2014) 
The adhesion cascade is well studied and includes a large number of molecules 
that take part in regulating lymphocyte migration in addition to the ones 
mentioned. Other selectins, integrins as well as ectoenzymes, such as CD73 and 
VAP-1 (Vascular Adhesion Protein 1), also play a role in lymphocyte migration. 
Moreover, during inflammation even more molecules are upregulated, which take 
part in the homing of neutrophils and other leukocytes. (Ley et al., 2007; Salmi and 
Jalkanen, 2014) After transmigrating through the HEV endothelial cells, 
lymphocytes still need to migrate through the surrounding ECM before reaching 
the lymph node parenchyma. Migration through the basement membrane 
surrounding HEVs is regulated by autotaxin, a secretory protein expressed by 
HEVs that is involved in the production of lysophosphatidic acid (LPA). When the 
autotaxin/LPA pathway is perturbed, lymphocytes are able to cross the endothelial 
cells of HEVs but they are retained between the endothelium and the basement 
membrane. (Bai et al., 2013; Hata et al., 2016) Once lymphocytes enter the lymph 
node parenchyma, their migration is regulated by other factors. 
2.3.3 Intranodal migration 
Naïve lymphocytes that have migrated via HEVs need to migrate into their 
designated areas in the lymph node parenchyma. When exiting the vasculature, T 
cells migrate along the complex stromal network of FRCs partly regulated by 
CCR7 and its ligands CCL19/21 secreted by FRCs. As DCs are enriched in this 
area of the lymph node, T cells are able to probe DCs in search for their cognate 
antigens while migrating throughout the lymph node. (Bajénoff et al., 2006a; 
Link et al., 2007; Worbs et al., 2007) Autotaxin, expressed by FRCs, also 
regulates the motility of T cells by signaling through LPA receptors expressed on 
T cells (Katakai et al., 2014; Takeda et al., 2016). Unlike in HEVs, chemokines 
in the lymph node parenchyma do not activate lymphocyte integrins due to lack 
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of shear stress. Therefore, intranodal T cell migration is independent of integrins. 
(Woolf et al., 2007) Upon the entry of naïve B cells from the blood vasculature, 
they concentrate around HEVs, where they can interact with DCs leading to early 
activation of B cells (Qi et al., 2006). In contrast to T cells, naïve B cells are 
retained around HEVs for hours and they do not enter B cell follicles readily. B 
cells are known to migrate along the FRC network towards the lymph node 
cortex (Bajénoff et al., 2006a) and their subsequent entry into the follicles is 
partly regulated by G protein coupled receptor (GPCR) -signaling. Dissimilar to 
naïve B cells, activated B cells exit the perivascular area efficiently and migrate 
directly into the follicles. (Park et al., 2012). B cell migration is mainly regulated 
by the chemokine receptor CXCR5 expressed by B cells, and its ligand CXCL13 
expressed by FDCs. CCR7 and CXCR4 have no role in regulating B cell 
migration in the lymph node parenchyma. Instead, signaling via the LFA-
1/ICAM-1 pathway supports CXCR5 regulated migration, albeit integrin 
signaling is not required for stromal cell supported migration. (Ansel et al., 2000; 
Coelho et al., 2013)  
2.3.4 Lymphocyte egress  
The main molecules regulating lymphocyte egress from peripheral lymph nodes are 
S1P and its receptor S1P1. S1P is produced intracellularly by all cells as an 
intermediate of sphingolipid metabolism, yet only extracellular S1P signals through 
its receptors. There are five different S1P receptors; all are GPCRs that signal via 
different Gαi subunits. Signaling can be efficiently abrogated with pertussis toxin. 
Of the five receptors, S1P1 regulates cell egress. Its expression correlates 
negatively to the concentration of S1P, as even low S1P concentrations cause 
internalization of the receptor. (Cyster and Schwab, 2012) S1P is produced by 
sphingosine kinases 1 and 2, and its concentration is high in plasma and lymph. 
Although lymph is considered a filtration of plasma, plasma S1P is produced by 
red blood cells whereas LECs are responsible for producing S1P in lymph. (Pappu 
et al., 2007; Pham et al., 2010) In LECs, the extracellular secretion of S1P is 
regulated by the sphingolipid transporter Spns2 (Mendoza et al., 2012). Tissue S1P 
concentration is very low due to S1P lyase that is expressed by hematopoietic cells 
and rapidly degrades S1P in the lymph node (Schwab et al., 2005). Differences in 
S1P concentrations result in high expression of S1P1 in lymphocytes in the lymph 
node, whereas lymphocytes in the blood stream and lymph downregulate the 
receptor due to ligand sensitization. 
Early studies discovered lymphocyte egress to be abrogated when treating 
mice with FTY720, an S1P analogue functioning as an S1P1 agonist. FTY720-
treatment causes lymphatic sinuses to be cleared from lymphocytes in addition to 
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causing lymphopenia. In the lymph node, lymphocytes are retained at the 
abluminal side of the sinus lymphatics and are tightly jammed against the 
endothelium. The same is true for lymphocytes devoid of S1P1. (Brinkmann et 
al., 2002; Mandala et al., 2002; Matloubian et al., 2004) FTY720, or fingolimod 
(sold as Gilenya), has proven to be a very effective immunosuppressive drug and 
it was the first oral drug available for the treatment of multiple sclerosis (Cyster 
and Schwab, 2012). 
Successful lymphocyte egress is a combination of chemotactic egress 
promoting signals that overcome the opposing retention signals. CCR7 promotes T 
cell retention in the lymph node and S1P–S1P1 signaling must overcome this for T 
cells to migrate into the lymphatic sinuses. T cells devoid of CCR7 exit more 
rapidly than their controls, and S1P1–/– T cells are able to egress even when 
chemokine signaling is abrogated with pertussis toxin. (Pham et al., 2008) Similar 
to T cells, B cell entry into lymphatic sinuses is induced by the S1P–S1P1 pathway. 
However, S1P chemotaxis plays no role in B cell egress. B cells that have occupied 
the lymph node for the most time gradually migrate from the central follicle to its 
rim, where they egress by entering the cortical sinuses. (Sinha et al., 2009) 
Lymphocyte egress takes place at the cortical sinuses, which are located near 
HEVs and B cell follicles in the cortex of the lymph node. These sinuses are 
densely packed with lymphocytes and connect directly to the medullary sinus. 
Lymphocytes can cross into the cortical sinus at multiple locations and 
sometimes several cells enter the sinus from the same site. This led to the concept 
of gateways in the LEC layer, which may support lymphocyte migration more 
readily. Lymphocytes encountering the sinus often migrate along its abluminal 
side, probe the sinus lumen and thereafter decide whether to cross the LEC layer 
or not. (Grigorova et al., 2009, 2010; Sinha et al., 2009) Adhesion of 
lymphocytes to the cortical sinus LECs has been reported to be independent of 
S1P1 signaling (Zhi et al., 2011). In fact, LFA-1 expressed by T cells mediates 
their adhesion and plays a role in deciding whether cells cross into the sinus, or 
whether they execute reverse migration back into the parenchyma (Reichardt et 
al., 2013). After crossing into the sinus, lymphocytes migrate along the sinus 
wall. There, they become captured by the lymphatic flow, which carries them to 
the medullary sinus. From thereon, lymphocytes get access to the subcapsular 
region surrounding the hilus area of the lymph node, and they drift with lymph 
into the efferent vessel leading to the next lymph node in the chain. (Grigorova et 
al., 2009) 
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Figure 5.  A schematic view of the murine Peyer’s patch depicting its major structures. Peyer’s 
patches constantly receive antigens from the intestinal lumen, which leads to 
prominent germinal centers (GC) in their B cell follicles (FOL). Peyer’s patches lack 
afferent lymphatics, and antigens arrive through the follicle-associated epithelium 
(FAE) through specialized M cells. Dendritic cells (DC) populate the subepithelial 
dome (SED) close to the FAE, and they present antigens to lymphocytes in 
interfollicular regions (IFR) or at the borders of follicles. Lymphocytes enter the Peyer’s 
patches via MAdCAM1+ HEVs and egress from the efferent lymphatics. 
2.4 Intestinal lymphocyte and antigen traffic 
The intestine is constantly exposed to antigenic stimuli originating from diet and 
the commensal microbiota. It can also be invaded by pathogenic factors rather 
easily. Therefore, it is no surprise that the intestine is the largest compartment of 
the immune system harboring the largest amount of immune cells in the body. 
Immune cells are present mostly in the small intestine and colon, in which they 
populate the mucosal layer of the intestinal wall and contribute to maintaining 
homeostasis. The intestinal epithelium is populated by CD8+ intraepithelial 
lymphocytes, whereas different subsets of CD4+ T cells and plasma cells reside in 
the lamina propria. (Agace and McCoy, 2017) Gut associated lymphoid tissue 
(GALT) contains small, diffuse structures as well as its most defined structures, 
Peyer’s patches, which are situated along the serosal layer of the intestine (Figure 
5). Peyer’s patches are comprised of large B cell follicles with reactive germinal 
centers (GC) and small T cell-rich IFRs. A unique structure of the Peyer’s patches 
is the follicle-associated epithelium (FAE). It separates the Peyer’s patch from the 
intestinal lumen and contains specialized microfold (M) cells involved in antigen 
transport. The subepithelial dome (SED) that harbors DCs and other immune cells 
is situated under the FAE. DCs internalize antigens and present them to T and B 
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cells in the SED. Unlike peripheral lymph nodes, Peyer’s patches are devoid of 
afferent lymphatics and only contain efferent lymphatics, which convey cell egress. 
(Mowat and Agace, 2014; Reboldi and Cyster, 2016) 
There are several lymph nodes draining the distinct regions of the gut. The 
chain of mesenteric lymph nodes (MLN) is comprised of many lymph nodes, 
which drain definite parts of the small intestine and colon. Regional draining of the 
gut allows for a lymph node specific cell composition in addition to a specific 
function. Lymph nodes draining the proximal part of the small intestine are 
tolerogenic and prevent food allergies, whereas lymph nodes draining the colon 
take part in pro-inflammatory responses. (Van den Broeck et al., 2006; Esterházy et 
al., 2019; Houston et al., 2016) 
2.4.1 Transporting intestinal antigens 
Intestinal antigens are acquired from the gut lumen, and they are transported to gut 
draining lymph nodes in the mesentery or into Peyer’s patches. Antigens can be 
transcytosed across the intestinal epithelium by epithelial cells. Thereafter, antigens 
are actively taken up by DCs and mononuclear phagocytes in the lamina propria. 
DCs and other phagocytes can also directly sample antigens from the gut lumen. 
Epithelial villi have a small number of M cells that may play a role in transporting 
luminal antigens. In contrast, M cells in the Peyer’s patch play a major role in 
transporting antigens from the intestine into the lymphoid tissue. Antigens are 
actively internalized by M cells via endocytosis, transcytosed and released into 
large pockets residing on the abluminal side of the cells. Immune cells, such as 
DCs and macrophages, can migrate into the M cell pockets, internalize, process the 
antigens and present them to T cells in the SED and IFR, or B cells in follicles. 
(Reboldi and Cyster, 2016; Schulz and Pabst, 2013) Activated B cells in the SED 
can also directly sample antigens from the basolateral pockets of the M cells 
(Komban et al., 2019). Similar to lymph nodes, Peyer’s patches also contain a 
reticular conduit structure that regulates fluid flow from the intestine to the 
lymphoid tissue. Small antigens are also transported throughout the Peyer’s patch 
by the conduit network. (Chang et al., 2019) Once antigens are available to DCs, 
antigen presentation and the following activation of lymphocytes and their 
effectory functions have the same basics as in the periphery, although molecules 
and pathways may be specific to the gut. 
2.4.2 Immune cell migration in gut lymphoid tissues 
Lymphocyte migration into gut draining lymph nodes of the mesentery and Peyer’s 
patches occurs mainly via the blood vasculature. The adhesion cascade has the 
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same steps as in peripheral lymph nodes; however, there are several gut specific 
molecules that regulate migration. Selectins are involved in lymphocyte rolling on 
HEVs by adhering to MAdCAM-1, which is specifically expressed in HEVs of the 
Peyer’s patch and partly in the MLN. Chemokine mediated activation of integrins 
is induced by CCL21–CCR7, CXCL12–CXCR4 and CXCL13–CXCR5 signaling. 
The subsequent lymphocyte arrest is mediated by the α4β7 integrin, the receptor for 
MAdCAM-1. In Peyer’s patches, B cells are more abundant than T cells in 
comparison to peripheral lymph nodes. Therefore, signaling via the CXCL13–
CXCR5 pathway as well as high expression of α4β7 integrin favors B cell entry into 
Peyer’s patches. Immune cell homing to the small intestine epithelium and lamina 
propria is regulated by CCL25–CCR9 and α4β7–MAdCAM-1 pathways. The 
specific gut-homing molecules expressed on lymphocytes are upregulated by DCs 
and stromal cells. (Habtezion et al., 2016; Reboldi and Cyster, 2016) 
The S1P–S1P1 pathway mainly regulates lymphocyte egress in Peyer’s patches 
(Pham et al., 2010). Chemokines are also involved in enabling egress from Peyer’s 
patches. CXCR4 on B cells and its ligand CXCL12 expressed by stromal cells 
promotes B cell entry into the efferent lymphatic vessels in Peyer’s patches. 
Opposing signals are supplied by CXCL13 expressed by FDCs trying to retain B 
cells in the follicles. (Schmidt et al., 2013) Interestingly, lymphocyte egress can 
also be regulated by the interplay of the nervous system and chemokine receptors. 
In the MLN, stimulation of the β2-adrenergic receptors on lymphocytes enhances 
retention signals. These signals are conveyed by the direct binding of the β2-
adrenergic receptors to CCR7 and CXCR4. Unlike in the Peyer’s patches, CCR7 
promotes B cell retention, whereas CXCR4 promotes T cell retention. (Nakai et al., 
2014) This demonstrates the complexity of regulating cell egress in different 
tissues, and reveals that the same molecules may have distinct, tissue-specific roles 
in regulating immune cell homeostasis. 
2.5 Inflammation induces changes in the lymph 
node 
During acute inflammation, the role of the adaptive immunity starts with the 
delivery of foreign antigens or pathogens to the draining lymph node and the 
activation of lymphocytes. Activated T cells undergo clonal expansion producing a 
large number of lymphocytes specific for the recognized antigen. These newly 
developed effector cells leave the lymph node and migrate to the site of 
inflammation (e.g. skin) to exert their effectory functions. Upon antigen 
recognition, B cells become activated, develop into plasma cells, and start 
producing specific antibodies against the foreign antigen. To accommodate all of 
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the aforementioned, the lymph node stroma goes under drastic changes as lymph 
nodes expand 5-10 fold during inflammation. (Acton and Reis e Sousa, 2016) 
During lymph node expansion BEC, LEC and FRC stromal cell compartments 
all undergo proliferation. HEVs dedifferentiate into an immature state and lose 
expression of HEV specific molecules. Expansion of the vascular compartment, 
which is necessary to support the increased entry of naïve lymphocytes to the 
lymph node, is regulated by DCs. DC-mediated signaling via the LTβR increases 
production of VEGF by FRCs, which promotes BEC proliferation. Permeability of 
blood vessels is increased during inflammation, which is also regulated by DCs. 
(Acton and Reis e Sousa, 2016; Dasoveanu et al., 2016; Thierry et al., 2019) The 
molecular composition of the endothelium changes as new players join in 
regulating the adhesion cascade and attracting other immune cells into the lymph 
node. (Ley et al., 2007; Muller, 2003; Salmi and Jalkanen, 2014) Simultaneously, 
lymphocyte egress is terminated causing total shutdown and retainment of 
lymphocytes in the lymph node to increase the likelihood of antigen recognition. 
During inflammation, T cells express CD69, which physically interacts with S1P1, 
causes its internalization resulting in diminished T cell egress. After 3 days, T cells 
regain S1P1 expression and are able to exit the lymph node and migrate to sites of 
inflammation. (Cyster and Schwab, 2012) 
Similar to BECs, LECs also undergo proliferation during inflammation. 
Proliferation requires an effective T cell response that provides the necessary 
stimuli to the lymph node stroma to induce LEC expansion. Proliferating LECs can 
retain antigens archiving them for up to several weeks in the draining lymph node. 
Antigen archiving results in increased inflammatory responses during secondary 
challenge leading to increased immune protection. (Tamburini et al., 2014) Lymph 
node LECs may also harbor Mycobacterium tuberculosis bacteria supporting 
extrapulmonary tuberculosis (Lerner et al., 2016). 
The reticular stroma reacts to facilitate the growing number of lymphocytes in 
the lymph node. During inflammation, DCs induce relaxation of FRCs to stretch the 
conduit and allow for expansion of the lymph node. FRC proliferation is further 
required for the stroma to increase in size and support the growing lymphocyte 
population. (Acton and Reis e Sousa, 2016; Dasoveanu et al., 2016) When 
inflammation is resolved, the lymph node stroma returnes to a resting state. Yet, the 
number of stromal cells remains elevated for several weeks after inflammation and 
antigens may reside in the lymph node for months. If inflammation is not resolved it 
becomes chronic, which involves the formation of tertiary lymphoid structures at 
extralymphoid sites in the periphery. Resolved inflammation leaves a scar damaging 
the local immune system, even if inflammation is resolved quickly. This scarring 
may have an effect on future immunological challenges and possibly even contribute 
to the development of chronic inflammation. (Acton and Reis e Sousa, 2016) 
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3 Aims 
Lymphocyte migration and the delivery of foreign antigens into the lymph node is 
central for mounting adaptive immune responses. Migrating immune cells and 
antigens both encounter the lymphatic endothelium when entering peripheral 
lymph nodes. Yet, the role of lymphatic endothelial cells in regulating cell 
migration or antigen transport is not fully comprehended. These studies were 
performed to elucidate the different regulatory functions of the lymph node 
lymphatics. The precise aims were: 
 
1. Investigating molecular differences in lymph node afferent and efferent 
LECs and the role of lymphatic Msr1 in regulating lymphocyte 
migration via the afferent lymphatics 
2. Studying the role of the efferent lymphatic marker Robo4 in regulating 
lymphocyte migration via the blood vasculature and lymphocyte egress 
in Peyer’s patches 
3. Describing the mechanism of the delivery of intact lymph-borne 
antibodies and other large antigens into the draining lymph node 
parenchyma 
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4 Materials and Methods 
4.1 Animals (I–III) 
Animal models were used in all publications of this thesis. Mice were housed in the 
animal facilities of the University of Turku, Finland and RWTH Aachen 
University, Germany. Animals were housed in open or individually ventilated 
cages with a light-dark cycle of 12 hours. All test subjects had ad libitum access to 
dried chow pellets and water. All animal experimentation was approved by the 
Ethical Committee for Animal Experimentation in Finland and Germany. 
Experiments were conducted according to the rules and regulations of The Finnish 
Act on Animal Experimentation (497/2013) with respect to the 3R-principle and 
performed under the following animal licences: 3791/04.10.03/2011, 
5587/04.10.07/2014, 6211/04.10.07/2017, 5762/04.10.07/2017 and 84-
02.04.2014.A330. 
Wild type (WT) strains of several different backgrounds were used for in vivo 
experiments, or as controls for knockout (KO) strains. C57BL/6J, C57BL/6N and 
BALB/C mice were purchased from Jackson Laboratories, Janvier Labs and 
Charles River Laboratories. Congenic CD45.1+ B6.SJL-Ptprca Pepcb/BoyJ were 
purchased from Jackson Laboratories. Genetically modified mouse models include 
B6.Cg-Msr1tm1Csk/J (Msr1 KO, stock 006096), Cav1tm1Mls/J (Caveolin 1 (Cav1) KO, 
stock 004585), FcRn-/- (Roopenian et al., 2003) and OTII mice (which express 
transgenic αβ T cell receptors specific for chicken ovalbumin (OVA)) that were 
purchased from Jackson Laboratories. 129S6(B6)-Robo4tm1Lex/Mmucd (Robo4 KO, 
stock 032543-UCD) and their WT controls with the same genetic background were 
purchased from Lexicon genetics Inc. and bred as separate lines. 
4.2 In vivo administered reagents (II, III) 
Fluorescent antibodies and dextrans were filtered using 10-kDa cutoff centrifugal 
units (MRCPRT010, Millipore) to remove any free fluorochromes and to 
concentrate antibodies. Mixtures of antibodies, 70 kDa TRITC dextran (D1818, 
Invitrogen) or 500 kDa FITC dextran (D7136, Invitrogen; II, III; see Table 2) were 
injected s.c. into the hind paws of recipient mice in volumes of 1–20 µl using 
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Microfine Demi 0.3 ml syringes (BD). For blocking experiments, the Fc binding 
function-blocking antibody was administered alone or with mouse 
immunoglobulins (010-0102-0005 Rockland) before, and with the test antibody 
mixture to block nonspecific binding to Fc receptors. In competition experiments, 
an unlabeled ratIgG2a monoclonal antibody (9B5 targeting human CD44) or 
mouse immunoglobulins were administered with test antibodies s.c. to recipient 
mice. During injections, the mice were under light isoflurane anesthesia. At 
predetermined timepoints, the mice were sacrificed; draining and non-draining 
lymph nodes were harvested and processed for microscopy or flow cytometry. 
To analyze vascular distribution of antibodies or to label BECs (II, III), 
fluorescent antibodies were administered to recipient mice with intravenous (i.v.) 
injections by injecting antibodies into the tail vein. After selected timepoints, mice 
were sacrificed and lymph nodes or Peyer’s patches were processed for imaging or 
flow cytometry. For detecting opposing structures of blood vessels, CD31-A594 
was administered s.c. followed by i.v. injections of PLVAP-A488. 
Fluorescein isothiocyanate (FITC, Sigma) was injected into Peyer’s patches to 
analyze turnover of lymphocytes (II). Mice were subjected to general anesthesia 
and the small intestine was surgically exposed. FITC was injected into 4-5 exposed 
Peyer’s patches/mouse (1 mg/ml) using fine glass capillaries connected to a 
microinjector. After the procedure, the small intestine was returned to the abdomen 
and surgical wounds were closed. Peyer’s patches were analyzed with flow 
cytometry after 24 hours. 
Table 2.  In vivo administered antibodies against mouse antigens. 
ANTIBODY ROUTE CLONE CAT. NO. COMPANY PUB. 
B220-eFluor 570 s.c. RA3-6B2 41-0452-80 eBioscience III 
B220-Pacific Blue s.c., i.v. RA3-6B2 558108 BD III 
CD3ε-FITC s.c. 145-2C11 553062 BD III 
CD4-AF647 s.c. RM4-5 557681 BD III 
CD4-FITC s.c., i.v. RM4-5 11-0042-81 eBioscience III 
CD4-PE s.c. RM4-5 553048 BD III 
CD8α-AF488 s.c. 53-6.7 557668 BD III 
CD8α-FITC s.c. 53-6.7 553031 BD III 
CD8α-FITC s.c. 3.155 FCMAB427F Milli-Mark III 
CD8α-HRP s.c. 53-6.7 MA1-10301 Thermo Scientific III 
CD11c-AF647 s.c., i.v. N418 117314 BioLegend III 
CD16/CD32 s.c. 2.4G2 553142 BD III 
CD16/CD32 s.c. 2.4G2 BE0307 Bio X Cell II 
CD19-FITC s.c. MB19-1 11-0191-81 Invitrogen III 
CD28 s.c. 37.51 16-0281 eBioscience III 
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ANTIBODY ROUTE CLONE CAT. NO. COMPANY PUB. 
CD28 s.c. B665 LS-C58166 LSBio III 
CD31-AF488 s.c. MEC13.3 102514 BioLegend III 
CD31-AF594 s.c., i.v. MEC13.3 102520 BioLegend III 
CD31-Biotin s.c. MEC13.3 553371 BD III 
CD31-DyL550 s.c. MEC7.46 NB100-1642R Novus Biologicals III 
CD45.2-BV711 s.c. 104 563685 BD III 
CD62L s.c. MEL-14 Gallatin, 
Weissman and 
Eugene, 1983 
In house III 
CD62L (Fab)2 s.c. MEL-14 Gallatin, 
Weissman and 
Eugene, 1983 
In house III 
CD90.2 s.c. 30-H12 105315 BioLegend III 
Collagen I s.c. pAb AB765P Millipore III 
ER-TR7-DyL405 s.c. ER-TR7 NB100-64932V Novus Biologicals III 
F4/80-AF647 s.c. CI:A3-1 MCA497A647 Biorad III 
H-2Kb-FITC s.c. AF6-88.5 116505 BioLegend III 
Ly6C-APC s.c. HK1.4 128016 BioLegend III 
MAdCAM-1 i.v. Meca367 Berg et al., 
1993 
In house II 
PNAd s.c. Meca79 Streeter, 
Rouse and 
Butcher, 1988 
In house III 
PLVAP-AF488 s.c., i.v. Meca32 120506 BioLegend III 
Robo4-AF647 s.c. FuRFM7 Fair-Mäkelä et 
al., 2020 
In house II 
Stabilin-1 s.c. 9-11 Palani et al., 
2011 
In house III 
Stabilin-1 (Fab)2 s.c. 9-11 Palani et al., 
2011 
In house III 
TCR β chain-PerCP Cy5.5 s.c. H57-597 560657 BD III 
Chicken IgG-AF647 s.c. pAb A21463 Invitrogen III 
Donkey IgM-AF647 s.c. pAb 715-605-140 Jackson III 
Goat IgM-AF647 (Fab) s.c. pAb 115-607-020 Jackson III 
Hamster IgG1-FITC s.c. A19-3 553971 BD III 
Hamster IgG2a-PerCP Cy5.5 s.c. B81-3 560562 BD III 
Rabbit IgM-AF647 s.c. pAb 315-605-020 Jackson III 
Rat IgG2a s.c. R35-95 553926 BD III 
Rat IgG2a s.c. Hermes-1 Jalkanen et al., 
1987 
In house III 
Rat IgG2a-AF488 s.c. RTK2758 400525 BioLegend III 
Sheep IgG-AF488 s.c. pAb 515-545-062 Jackson III 
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4.3 In vivo experiments (I–III) 
4.3.1 Adoptive transfer assays (I, II) 
Lymphocytes were mechanically isolated from the spleen, skin-draining and 
cervical lymph nodes of WT donor mice, and labeled with 0.5 µM CellTrace CFSE 
(C34554, Invitrogen). 10x106 or 1x106 cells were injected s.c. into the footpads of 
recipient mice; Msr1 KO, Robo4 KO and their WT controls, while mice were 
under light isoflurane anesthesia. Lymphocytes were let to migrate into the 
draining popliteal lymph nodes (and further to the sacral and iliac lymph nodes) for 
4.5 or 12 hours. The number of transferred cells was analyzed with flow cytometry, 
and their localization was examined with fluorescence imaging. 
For studying the role of vascular Robo4 in lymphocyte migration, 
lymphocytes were isolated from the skin-draining, mesenteric and cervical lymph 
nodes of congenic CD45.1+ donor mice. Lymphocytes (12x106 cells/recipient) 
were injected i.v. into CD45.2+ Robo4 KO and their WT controls. After 2 or 18 
hours, mice were sacrificed and the number and localization of adoptively 
transferred cells was analyzed from peripheral lymph nodes (inguinal, axillary, 
brachial), MLN, Peyer’s patches and peripheral blood using flow cytometry and 
fluorescence imaging.  
4.3.2 Activation of T cells (III) 
Activation of T cells was performed by administrating anti-TCR and anti-CD3 
antibodies, or their isotype specific controls, by s.c. injections into the footpads of 
recipient mice. After 5 min or 18 hours, the draining and non-draining popliteal 
lymph nodes were isolated and T cell activation was determined by examining the 
early activation markers CD69 and CD25 with flow cytometry.  
In another set of experiments, splenocytes were isolated from CD45.2+ OTII 
donor mice (specifically recognizing OVA), enriched for naïve CD4+ T cells with 
the EasySep Mouse Naïve T cell isolation kit (19765, Stemcell Technologies) and 
labeled with 1 µm CellTrace CFSE. 5x106 lymphocytes were adoptively 
transferred into CD45.1+ recipient mice by i.v. injections, and they were allowed to 
distribute to secondary lymphoid organs for 18 hours. To stimulate T cell 
proliferation, an agonistic anti-CD28 antibody (clone D665) or an inhibitory 
antagonistic anti-CD28 antibody (clone 37.51) was administered s.c. to the 
recipient mice along 2 µg of OVA (321000, Hyglos). OVA combined with the 
adjuvant, lipopolysaccharide (LPS, L3024, Sigma) was used as a positive control. 
After 3 days, the draining and non-draining popliteal lymph nodes were isolated 
and the proliferation of the transferred OTII cells was analyzed with flow 
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cytometry. Cells were separated into CFSEhi (undivided) or CFSElo (divided ≥5 
times), and the absolute number of any CFSE+ cells was determined from the 
whole tissue. 
4.3.3 Uptake of antigens (III) 
To analyze the uptake of foreign antigens after s.c. injections, 2 µg of recombinant 
human AOC3 protein (150-16, PeproTech) labeled with Alexa Fluor 647 was 
injected s.c. into recipient mice. Draining popliteal lymph nodes as well as lymph 
nodes from untouched mice were collected after 2 hours and processed for flow 
cytometry or microscopic analyses. 
4.3.4 Depletion of macrophages (I, III) 
Resident lymph node macrophages were depleted with s.c. injections of clodronate 
or vehicle containing liposomes to the footpads of recipient mice (Rooijen and 
Sanders, 1994). When antibodies were also administered to the same footpad, 
clodronate was administered to the anterolateral surface of the tibia and antibodies 
were injected into the footpad of the same paw three days later. 
4.3.5 Blocking of endocytosis (III) 
Endocytosis was blocked using the following chemical inhibitors targeting clathrin 
(Pitstop 2 (ab120687, Abcam) and monodansylcadaverine (MDC, D4008, Sigma)), 
dynamin (Dyngo-4a (A511904, Sigma) and Dynole 34-2 (ab120463, Abcam)), 
macropinocytosis (EIPA [5-(N-ethyl-N-isopropyl amiloride] (A3085, Sigma)) and 
a chemical stabilizing interendothelial junctions (adrenomedullin (NC0928729, 
Phoenix Pharmaceuticals)). Popliteal lymph nodes were surgically exposed while 
mice were under general anesthesia. The inhibitors and their appropriate negative 
controls were administered directly onto the exposed popliteal lymph nodes as 
fresh droplets for 15 min. Test antibodies were injected s.c. into the footpads of 
treated mice and lymph nodes were collected after 5 min. 
4.3.6 Monoclonal antibody production (II) 
A Robo4 KO mouse was immunized with 5 µg recombinant murine Robo4 
(MBS2546674, MyBioSource) in Freund’s Incomplete Adjuvant by s.c. injections 
into the footpad once a week for three weeks. The draining popliteal lymph node 
was collected, fused to the mouse myeloma cell line SP2/0 followed by the 
production of hybridoma cell lines using the ClonaCell-HY Hybridoma Kit (03800, 
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Stemcell Technologies) according to the manufacturer’s instructions. Cell lines 
were cultured in Dulbecco’s modified eagle medium (D6429, Sigma), positive 
clones detecting Robo4 were adapted to serum free CD Hybridoma medium 
(11279-023, Gibco) and the buffer was changed to PBS while concentrating the 
antibodies with 100-kDa cutoff centrifugal filter units (UCF910024, Millipore). 
Isotypes were determined using the Pierce Rapid Antibody Isotyping Kit plus 
Kappa and Lambda – Mouse (26179, Thermo Scientific). The antibody was 
validated with an enzyme-linked immunosorbent assay (ELISA), flow cytometry 
and immunofluorescence imaging using Robo4 overexpressing Hek cells. 
4.4 Flow cytometry (I–III) 
4.4.1 Preparing single-cell suspensions (I–III) 
Single-cell suspensions were prepared from peripheral lymph nodes (PLN, I–III), 
MLN (II), Peyer’s patches (II) and the bone marrow (II). Lymphocytes were 
extracted from lymph nodes and Peyer’s patches with mechanical homogenization 
using cell strainers, followed by washing and filtering the samples to remove tissue 
remnants. To isolate B cell progenitors from the bone marrow (II), femurs were 
collected and crushed with a mortar in Hanks’ buffered salt solution (HBSS) 
supplemented with 2% fetal calf serum (FCS). When analyzing peripheral blood, 
erythrocytes were lysed with hypotonic solutions (II). 
For detection of antigen presenting cells (III), lymph nodes were mechanically 
minced into small pieces that were enzymatically digested in HBSS containing 
collagenase D (1 mg/ml) and DNase I (50 µg/ml) for 30 min at +37 °C. Endothelial 
cells were isolated from peripheral lymph nodes, MLN, Peyer’s patches and the 
skin (I, II) with enzymatic digestion. The samples were mechanically minced and 
incubated several times with an enzymatic cocktail containing Liberase (25 µg/ml) 
and DNase I (100 µg/ml) or collagenase P (0.2 mg/ml) and neutral protease (0.8 
mg/ml) in phosphate buffered saline (PBS) at +37 °C with gentle agitation. 
4.4.2 Staining and acquiring samples (I–III) 
After obtaining single-cell suspensions, samples were stained with primary 
antibodies followed by fluorescently labeled secondary antibodies, or with 
fluorescently conjugated antibodies (Table 3). Unspecific antibody staining was 
blocked with an anti-CD16/CD32 Mouse BD Fc Block (BD 553141) or 5% rat 
serum. Antibodies were added to cells, incubated on ice and samples were fixed 
using paraformaldehyde (PFA) supplemented buffer. The apoptotic rate of 
lymphocytes was analyzed using the Annexin V staining according to the 
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manufacturer’s instructions. For analyzing samples with cytometers (I-III), cells 
were acquired using a LSR II (I) or LSR Fortessa (II, III) both from BD. Samples 
were analysed using FlowJo software (FlowJo, BD). 
4.4.3 Fluorescence-activated cell sorting (I) 
Stromal cells were isolated from enzymatically digested peripheral lymph nodes 
and MLNs collected from C57BL/6J mice. Samples were stained for the 
appropriate markers (Lineage cocktail, podoplanin, CD73 or their isotype controls) 
and 7-AAD to exclude dead cells. For isolating mouse LECs for cell culturing, 
samples were stained with Lineage cocktail, CD45, CD11b, podoplanin, CD31 and 
LYVE1. Cells were sorted with FACSAria II (BD), CD73+ or CD73– LECs 
(Lineage– podoplanin+) were collected for RNA extraction and Lineage– CD45– 
CD11b– podoplanin+ CD31+ LYVE1+ cells were subjected for cell culturing. 
Table 3.  Antibodies against mouse antigens used in flow cytometry and cell sorting. 
ANTIBODY CLONE CAT. NO. COMPANY PUB. 
Annexin V-PE - 556422 BD II 
B220-Pacific Blue RA3-6B2 558108 BD I, III 
B220-PE RA3-6B2 561878 BD I 
B220-BV421 RA3-6B2 562922 BD II 
CD1d-PerCP Cy5.5 1B1 562713 BD II 
CD3-AF647 17A2 557869 BD II, III 
CD3-PerCP Cy5.5 17A2 100218 BioLegend III 
CD4-AF647 RM4-5 557681 BD I, III 
CD4-APC Cy7 GK1.5 552051 BD I, II, III 
CD4-BV510 RM4-5 100553 BioLegend II 
CD4-FITC RM4-5 11-0042-81 BioLegend III 
CD4-V500 RM4-5 560782 BD III 
CD5-PE 53-7.3 553023 BD II 
CD8α-BV650 53-6.7 563234 BD I, II, III 
CD8α-BV711 53-6.7 100747 BD II 
CD8α-FITC 53-6.7 553031 BD III 
CD8α-FITC 3.155 FCMAB427F Milli-Mark III 
CD8α-PerCP Cy5.5 53-6.7 551162 BD I, III 
CD11b-APC M1/70 553312 BD I 
CD11b-APC Cy7 M1/70 561039 BD I, II 
CD11b-PE M1/70 553311 BD III 
CD11c-BV421 HL3 562782 BD III 
CD16/CD32 2.4G2 553141 BD I, II, III 
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ANTIBODY CLONE CAT. NO. COMPANY PUB. 
CD19-APC Cy7 1D3 557655 BD II 
CD19-BV421 6D5 115537 BioLegend II 
CD19-BV510 1D3 562956 BD II 
CD24-BV650 M1/69 563545 BD II 
CD25-PE PC61 553866 BD III 
CD31-APC MEC13.3 102510 BioLegend I, II 
CD40-PE CF594 3/23 562847 BD II 
CD43-BV605 S7 563205 BD II 
CD44-APC IM7 17-0441-82 eBioscience II 
CD44-PerCP Cy5.5 IM7 560570 BD II 
CD45-APC Cy7 30-F11 557659 BD I, II 
CD45-FITC 30-F11 553079 BD II 
CD45-PE 30-F11 553081 BD II 
CD45-V500 30-F11 561487 BD III 
CD45.1-FITC A20 553775 BD II 
CD45.2-APC 104 558702 BD II, III 
CD45.2-PerCP Cy5.5 104 552950 BD III 
CD62L-BV421 MEL-14 104436 BioLegend II 
CD62L-AF647 MEL-14 104417 BioLegend II 
CD69-APC H1.2F3 17-0691-80 eBioscience I 
CD73-PE TY23 550741 BD I 
CD95-PE Jo2 554258 BD II 
CD169-BV605 3D6.112 142413 BioLegend III 
Endomucin V.5C7 MAB2624 Millipore I 
Endomucin-eFluor 660 V.7C7 50-5851 eBioscience I 
F4/80-AF488 BM8 MF48020 Invitrogen III 
GL7-AF647 GL7 561529 BD II 
Lineage Ab cocktail-APC - 558074 BD I 
Lineage Ab cocktail isotype-APC - 558074 BD I 
LYVE1 pAB 103-PA50 ReliaTech GmbH I 
LYVE1-PE 223322 FAB2125P R&D Systems I, II 
MHCII-PE Cy7 M5/114.15.2 25-5321-82 eBioscience II, III 
Podoplanin-PE Cy7 8.1.1 127412 BioLegend I, II 
Robo4 274940 MAB5004 R&D Systems II 
Robo4 FuRFM7 Fair-Mäkelä 
et al., 2020 
In-house II 
Robo4-PE 274914 FAB50041P R&D Systems II 
Streptavidin-AF488 - S11223 Invitrogen I 
Mouse IgD-BV786 11-26c.2a 563618 BD II 
Mouse IgG1 Ak1 - InVivo BioTech II 
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ANTIBODY CLONE CAT. NO. COMPANY PUB. 
Mouse IgM APC-eFluor780 II/41 47-5790-80 eBioscience II 
Rat IgG1-FITC RTK2071 400405 BioLegend I 
Rat IgG2a-eFluor 660 eBR2a 50-4321-82 eBioscience I 
Rat IgG2a-FITC R35-95 553929 BD I, II 
Rat IgG2a-PE R35-95 553930 BD I, II 
Rat IgG2a-PE 54447 IC006P R&D Systems II 
Rat IgG2b-FITC A95-1 556923 BD I 
Donkey anti-mouse IgG-AF647 pAb A31571 Invitrogen II 
Goat anti-rat IgG-AF488 pAb A11006 Invitrogen III 
Goat anti-rat IgG-FITC pAb F6258 Sigma-Aldrich I, II 
4.5 Processing samples for microscopy (I–III) 
Lymph nodes, MLN and Peyer’s patches were harvested from mice and embedded 
in optimal cutting temperature (OCT) medium. Peyer’s patches were collected 
attached to the small intestine and fixed with 4% PFA for 2–4 hours at +4 °C, 
washed with PBS twice for 10 min and incubated in 30% sucrose overnight. 
Popliteal LNs and Peyer’s patches were embedded in OCT in a predetermined 
orientation to produce transverse sections of the tissues. For some stainings, 
Peyer’s patches were mounted without PFA fixing. Tissue blocks were snap frozen 
using dry ice, stored at –70 °C and used for cutting 6 µm sections. In some cases, 
lymph node samples were embedded in paraffin. Tissue sections were stained with 
primary antibodies followed by fluorescently conjugated secondary antibodies, or 
fluorescently conjugated antibodies using predetermined antibody concentrations at 
room temperature (Table 4). Sections were overlaid with ProLong Gold Antifade 
Mountant with or without DAPI (Invitrogen, P36931 and P10144, respectively). 
Late apoptotic cells were stained from fixed Peyer’s patch sections using the Click-
IT Plus TUNEL Assay (C10618, Invitrogen) according to the manufacturer’s 
instructions. 
Lymph nodes containing s.c. delivered antibodies were not subjected to any 
additional antibody staining unless indicated (ex vivo staining). When detecting the 
unlabeled, free antibody (rat IgG2a), the antibody was fixed in situ. Thirty seconds 
after the injection of the free antibody, 4% PFA was injected s.c. into the same 
footpad. Ninety seconds later, the mice were sacrificed and lymph nodes were 
processed for microscopy. Before staining with antibodies, the sections were 
further fixed with 4% PFA for 5 min at +4 °C, washed with PBS and quenched 
with 0.1 M glycine. Lymph nodes s.c. injected with lysine-fixable dextrans were 
similarly fixed in situ and ex vivo. Popliteal lymph nodes from untouched mice 
were fixed identically to serve as proper controls. 
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Staining for the early endosomal marker EEA1 was perfomed the following 
way: frozen sections were washed, fixed with 4% PFA for 15 min at room 
temperature, washed twice with PBS and quenched with 50 mM NH4Cl for 15 min 
at room temperature. Samples were blocked with 30% horse serum and 
permeabilized with 0.3% Triton-X. Sections were stained with the EEA1 antibody 
followed by Alexa Fluor 546-conjugated anti-rabbit IgG antibody. HRP-conjugated 
antibodies were administered s.c. and visualized using DAB as a substrate. 
For electron microscopy, samples were fixed, dehydrated and embedded with 
45359 Fluka Epoxy Embedding Medium kit. For immunoelectron microscopy, the 
free antibody was injected s.c. into recipient mice. After 2 min, the mice were 
perfused with warmed PBS and tissues were perfusion fixed. Draining lymph nodes 
were collected, fixed and incubated in 2.1 M sucrose at +4 °C overnight for 
cryoprotection. The lymph nodes were snap-frozen, cut into 10 µm sections and 
stained with 10 nm gold-conjugated anti-rat IgG (EM.GAT10, BBI Solutions) 
Samples were further processed for imaging and embedded on microscope slides. 
Using an ultramicrotome, 70 nm sections were cut and stained with 1% uranyl 
acetate and 0.3% lead citrate for both transmission and immunoelectron microscopy. 
4.6 Imaging and image analysis (I–III) 
4.6.1 Acquiring images (I–III) 
Fluorescence images were acquired using an Olympus BX60 fluorescence 
microscope (Tokyo, Japan) equipped with an UPlanFI 20x/0.50 or UPlanFI 
40x/0.75 objective. Alternatively, images were acquired with a Nikon Eclipse TI-E 
fluorescence microscope with a Plan Apo lamda 20x/0.80 objective. Electron 
microscopy samples were examined using a JEM-1400 Plus transmission electron 
microscope (JEOL). 
Confocal images were imaged using a LSM780 or LSM880 confocal 
microscope (Carl Zeiss) with Plan-Apochromat 20x/0.8 and c-Apochromat Korr 
M27 40x/1.20 objectives. Intracellular EEA1+ vesicles were imaged with the 
LSM880 confocal microscope using an Airyscan detector (Carl Zeiss) and a C 
Plan-Apochromat 63x/1.4 oil objective. Images were acquired with the Zen 2010 
of Zen 2.3 SP1 FP2 software (Carl Zeiss). The slice thickness was determined by 
adjusting the pinhole and the same thickness was used for each channel. In some 
cases, images were acquired with the Intelligent Imaging Innovations (3i) Marianas 
Spinning disk confocal microscope (Intelligent Imaging Innovations) with the Plan 
Apochromat 20x/0.8 N.A. objective and SlideBook 6 software. 
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4.6.2 Image analysis (I–III) 
Image analyses were performed with ImageJ software (NIH). Linear brightness 
adjustments and background subtraction was applied equally to all images and their 
controls (I–III). The shortest distance of the adoptively transferred CFSE+ 
lymphocytes from the SCS was measured by hand with Zen 2012 software (Carl 
Zeiss) while omitting lymphocytes in the medullary sinus from the analyses (I). 
Mean fluorescence intensity was analyzed from defined zones starting from the 
SCS and proceeding towards the lymph node parenchyma after s.c. injections of 
free monoclonal antibody or dextrans (III). Localization of the free antibody in 
respect to conduit markers across reference lines was analyzed using the ImageJ 
plugin, RGB Profiler. In these analyses, the core of the conduit was defined as 
collagen I signal bordered by ER-TR7 signal (III). EEA1+ vesicular structures and 
free antibody vesicles from the CD31+ SCS floor LECs were analyzed using Imaris 
8.1.2 software (Bitplane). Free antibody vesicles were detected with the ‘Spots’ 
tool and the surface of EEA1+ vesicles was modeled using the ‘Surface’ tool. The 
free antibody vesicles in direct contact or immediate vicinity of EEA1+ structures 
were manually enumerated (III). 
For analyzing the areas of any selected positive signal, the appropriate signal 
determined by thresholding was analyzed in relation to the region of interest. Such 
image analyses were utilized when analyzing the anatomic localization of 
lymphocytes, blood and lymphatic vessels, adoptively transferred CD45.1+ cells, 
TUNEL+ apoptotic cells and collagen I+ signal (II). 
4.6.3 Tissue whole mount imaging (I, III) 
For whole mount imaging of skin lymphatics (I), ears were collected from Msr1 
KO and WT mice. Dorsal halves of the mechanically separated ears were fixed 
with 2% PFA, blocked for nonspecific staining with 1% normal mouse serum and 
0.5% FCS in PBS-MT (PBS with 1% skim milk and 0.4% Triton X-100 (Sigma)) 
and stained for Msr1 and LYVE1. Ears were mounted onto microscopic slides and 
topped with coverslips. Samples were imaged using the Intelligent Imaging 
Innovations (3i) Marianas Spinning disk confocal microscope and the 20x/0.8 
objective. 
For whole mount imaging of the popliteal lymph nodes (III), 10 µg of 
fluorescently conjugated antibodies were injected s.c. into recipient mice and 
antibodies were let to drain to the lymph node for 30 min. Lymph nodes were 
harvested, fixed and dehydrated with methanol. For optical clearing, lymph nodes 
were incubated with 50% BABB diluted in MetOH (BABB was prepared by 
mixing one part benzyl alcohol with two parts benzyl benzoate) followed by 100% 
BABB until the tissue was clear. Samples were imaged using the LSM780 confocal 
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microscope (Carl Zeiss) and Plan-Apochromat 20x/0.8 objective by taking z stacks 
with a 5 µm slice thickness. Background subtraction and linear brightness 
adjustments were performed with the Imaris 8.1.2 software (Bitplane), which was 
also used to create a three-dimensional image reconstruction. 
Table 4.  Antibodies against mouse antigens used in microscopy, adhesion assays and ELISA. 
ANTIBODY CLONE CAT. NO. COMPANY PUB. 
B220-Pacific Blue RA3-6B2 558108 BD I, II 
B220-eFluor 570 RA3-6B2 41-0452-80 eBioscience II, III 
CD4-AF647 RM4-5 557681 BD I, II 
CD8α-AF488 53.6-7 557668 BD I, II 
CD11c-FITC N418 117306 BioLegend III 
CD19 6D5 115502 BioLegend II 
CD19-AF647 6D5 115522 BioLegend II 
CD31-AF488 MEC13.3 102514 BioLegend I, II, III 
CD31-AF594 MEC13.3 102520 BioLegend III 
CD31-AF647 390 102415 BioLegend III 
CD31-APC MEC13.3 102510 BioLegend III 
CD44-FITC IM7 553133 BD II 
CD45.1-Biotin A20 110704 BioLegend II 
CD62L MEL-14 (Gallatin et al., 
1983) 
In house II 
CD169-FITC 3D6.112 MCA884F Biorad I, III 
CD204-AF488 2F8 MCA1322A488 Biorad I 
CD204-AF647 2F8 MCA1322A647 Biorad I 
Collagen I pAb AB765P Millipore II, III 
EEA1 pAb C45B10 Cell Signaling Technology III 
Endomucin V.57C MAB2624 Millipore I 
ER-TR7-DyL 405 ER-TR7 NB100-64932V Novus Biologicals III 
F4/80-PE Texas Red BM8 MF48017 Invitrogen I 
IgD-AF647 11-26c.2a 405708 BioLegend II 
LYVE1 pAb 103-PA50 ReliaTech GmbH II 
LYVE1 223322 FAB2125G BD I 
LYVE1-AF488 ALY7 53-0443-82 eBioscience II 
Ly6C-APC HK1.4 128016 BioLegend III 
MAdCAM-1 Meca367 Berg et al., 
1993 
In house II 
Msr1 2F8 LS-C124019 LSBio I 
Msr1 pAb GTX51749 GeneTex I 
PLVAP Meca32 Hallmann et al., 
1995 
In house I, II 
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ANTIBODY CLONE CAT. NO. COMPANY PUB. 
PNAd Meca79 Streeter, Rouse 
and Butcher, 1988 
In house III 
Podoplanin 8.1.1 ab111127 Abcam I 
Robo4 FuRFM7 Fair-Mäkelä et 
al., 2020 
In house II 
Robo4 pAb bs-5795r Bioss Antibodies II 
Siglec-1 3D6.112 MCA884EL Biorad I 
Smooth muscle actin-Cy3 1A4 C6198 Sigma-Aldrich III 
Donkey anti-goat IgG AF488 pAb A11055 Invitrogen II 
Donkey anti-goat IgG AF546 pAb A11056 Invitrogen I 
Donkey anti-goat IgG AF633 pAb A21082 Invitrogen II 
Goat anti-hamster IgG AF488 pAb A21110 Invitrogen I 
Goat anti-hamster IgG AF546 pAb A21111 Invitrogen I 
Goat anti-mouse IgG AF488 pAb A11029 Invitrogen II 
Goat anti-rabbit IgG AF488 pAb A11034 Invitrogen I 
Goat anti-rabbit IgG AF546 pAb A11035 Invitrogen I, II, III 
Goat anti-rabbit IgG AF633 pAb A21071 Invitrogen III 
Goat anti-rat IgG AF488 pAb A11006 Invitrogen I, II, III 
Goat anti-rat IgG AF546 pAb A11081 Invitrogen I, II 
Goat anti-rat IgG AF647 pAb A21247 Invitrogen I 
Goat anti-rat IgM AF488 pAb A21212 Invitrogen III 
4.7 Laser capture microdissection (I) 
Peripheral lymph nodes collected from C57BL/6J mice were snap-frozen, stained 
with CD31 and F4/80 to determine endothelial cells and macrophages, and used for 
exctraction of LECs with laser capture microdissection. Cells were excised from 
the SCS and cortical sinus region representing the afferent and efferent lymphatics 
by using a Zeiss PALM MicroBeam instrument and a 40x objective. Dissected 
cells were collected into adhesive caps containing lysis buffer and subjected for 
RNA extraction. 
4.8 Microarray analysis (I) 
LECs representing the afferent and efferent lymphatics of the lymph node were 
isolated by flow cytometry and laser capture microdissection and used for 
performing a genome-wide microarray assay. RNA extraction, translation into 
complementary DNA and hybridization to the Agilent Whole Mouse Genome 
Oligo Microarrays 8x 60 K was performed at Miltenyi Biotec. Appropriate 
bioinformatic analyses were conducted to analyze differentially expressed genes 
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between the afferent and efferent lymphatics. The data obtained from the 
microarray is deposited to the GEO archive (GSE 68371). 
4.9 In vitro experiments 
4.9.1 Human material (I, II) 
Lymph nodes and appendix samples were collected from the surplus tissues of 
patients undergoing surgical operations. Tissues that appeared to be normal after 
macroscopic and microscopic inspection were used for further analyses. 
Mononuclear cells were isolated from healthy volunteers with the appropriate 
permission granted by the Ethical Committee of the Turku University Hospital. 
4.9.2 Ex vivo adhesion assays (I, II) 
Human lymphocytes or CFSE labeled mouse lymphocytes were incubated on 
freshly cut frozen sections of human or mouse lymph nodes, or primary mouse 
LECs treated with blocking antibodies against Msr1, Robo4 or negative controls 
(see Tables 4 and 5). Lymphocytes were let to bind to lymph nodes for 5 min under 
rotation, 15 min at steady conditions, 5 min under rotation and 15 min at steady 
conditions at +7 °C. Mouse lymphocytes were incubated on lymph nodes for 30 
min at +7 °C under rotation. Unbound cells were decanted off and bound cells were 
fixed with 1% glutaraldehyde. The number of bound lymphocytes was enumerated 
manually under dark-field microscopy and control values were set to 100% by 
definition. 
The extracellular domain of murine Msr1 cloned from murine Msr1 cDNA 
(OMG222674, Origene) was fused to the human IgG2 Fc tail to generate an Msr1-
Fc chimera. The Msr1-Fc chimera or control Ig were incubated with lymphocytes 
isolated from mouse lymph nodes for 30 min at RT. Binding of the chimera was 
detected with a biotinylated anti-human Ig antibody followed by Alexa Fluor 488 
conjugated Streptavidin (see Table 5). Lymphocytes were stained with lymphocyte 
markers and samples were ran with LSR Fortessa (BD). 
4.9.3 Culturing primary cells (I) 
Mononuclear cells were isolated from the peripheral blood of healthy donors and 
enriched for monocytes using negative or positive selection kits (Miltenyi Biotec). 
Monocytes were polarized towards M1 or M2 macrophages by culturing them with 
M-SCF 10 ng/ml (574804, BioLegend) for six days and polarizing them for one 
day with IFN-γ 20 ng/ml (285-IF-100, R&D Systems) or IL-4 20 ng/ml (200-04, 
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PeproTech), respectively. Control cells (M0) were cultured with M-CSF for seven 
days. Commercially available primary human lymphatic endothelial cells (HLEC) 
isolated from lymph nodes (Catalog #2500, ScienCell Research Laboratories) or 
human dermal lymphatic endothelial cells (HDLEC) isolated from skin (C-12216, 
PromoCell) were cultured in the appropriate culture media supplemented with 
serum and antibiotics. Cells were harvested and subjected for RNA extraction.  
Stromal cells were isolated from peripheral and mesenteric lymph nodes of WT 
mice with enzymatic digestion and cultured for 7 days in Complete mouse 
endothelial cell medium /w Kit (M1168, Cell Biologics). LECs were enriched with 
cell sorting, cultured for a further 7 days and used for performing adhesion assays. 
Table 5.  Antibodies against human antigens used in microscopy and adhesion assays. 
ANTIBODY CLONE CAT. NO. COMPANY PUB. 
Clever-1 3-372 Irjala et al., 2003 In-house II 
IgG Fc-biotin pAb ab98561 Abcam I  
Msr1 pAb ab123946 Abcam I 
LYVE1 pAb 103-PA50 ReliaTech GmbH II 
Prox-1 pAb AF2727 R&D Systems II 
Robo4 pAb NB110-58780 Novus Biologicals II 
Robo4 pAb ab10547 Abcam II 
Siglec-1 HSn 7D2 ab18619 Abcam I 
Streptavidin AF488 - S11223 Invitrogen I 
4.9.4 RT-PCR and qPCR (I, II) 
RNA was extracted from human macrophages (M0, M1 and M2), cultured primary 
human LECs and murine B cells isolated from Peyer’s patches with the B cell 
Isolation Kit (130-090-682, Miltenyi Biotec). RNA extraction was performed using 
the NucleoSpin RNA extraction kit (740955.250, Macherey-Nagel) and RNA was 
transcribed to complementary DNA with the SuperScript VILO cDNA Synthesis 
kit (11754050, Invitrogen). RT-PCR reactions were conducted with Kapa2G 
Robust PCR Kit (Kapa Biosystems) and quantitative PCR (qPCR) was performed 
using the TaqMan Universal Master Mix II (4440038, Thermo Fisher Scientific) 
with probes and primers designed with the Universal Probe Library Assay Design 
Center (Roche Life Science, Table 6). qPCR reactions were ran with the Applied 
Biosystems’ Quant Studio 3 Real-Time PCR System (Thermo Fisher Scientific) 
and the Applied Biosystem’s analysis modules available in the Termo Fisher Cloud 
computing platform were used to calculate relative expression levels. Results are 
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presented as the percentage of control gene (Actb) mRNA levels from the same 
sample. 
Table 6. Primers used for RT-PCR and qPCR. 
GENE PRIMER SEQUENCE PROBE PUB. 
Actb (human) Left 
Right 
tgacggggtcacccacactgtgcccatcta 
ctagaagcatttgcggtggacgatggaggg 
- I 
Actb (mouse) Left 
Right 
ctaaggccaaccgtgaaaag 
accagaggcatacagggaca 
64 II 
Msr1 (human), 
variants 1 and 3 
Left 
Right 
caggtccaataggtcctccggg (F1) 
gagcagcgatttcatagttgtg (R1) 
- I 
Msr1 (human), 
variant 2 
Left 
Right 
caggtccaataggtcctccggg (F1) 
gtatgagcatgggagcagaggc (R2) 
- I 
Cxcr4 (mouse) Left 
Right 
tggaaccgatcagtgtgagt 
gggcaggaagatcctattga 
38 II 
Cxcr5 (mouse) Left 
Right 
gaatgacgacagaggttcctg 
gcccaggttggcttcttat 
13 II 
S1pr1 (mouse) Left 
Right 
cggtgtagacccagagtcct 
agcttttccttggctggag 
66 II 
4.10 Statistical analyses (I–III) 
Experimental sample sizes were determined using pilot assays and experiments 
were conducted in a non-blinded fashion. The numerical data is presented as mean 
± SEM or mean ± SD. For comparing results between two treatment groups or 
genotypes, data was analyzed using the Student’s t test, Mann-Whitney U test or 
the Wilcoxon matched-pairs signed-rank test. For comparisons between multiple 
groups, data was analyzed with the Kruskal-Wallis test followed by Dunn’s test 
when applicable. To analyze fluorescence intensities in different zones of the 
lymph node, linear regression analyses were applied to the data. Statistical analyses 
were conducted with GraphPad Prism or SAS 9.4 software. P values under 0.05 
were considered as statistically significant. 
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5 Results 
5.1 Differentially expressed genes in lymph node 
afferent and efferent LECs (I) 
Molecular differences of the lymph node afferent and efferent LECs have not been 
thoroughly studied before. Therefore, we set out to analyze the genetic differences 
among these populations. LECs were isolated from lymph nodes by using 
fluorescence-activated cell sorting and laser capture microdissection. LECs were 
sorted as Live/Lineage- podoplanin+ cells and they were further divided into 
afferent and efferent populations based on expression of CD73, a marker for the 
afferent lymphatics (Ålgars et al., 2011).. For laser capture microdissection, LECs 
were distinguished by their expression of CD31, while F4/80 was used to label 
lymph node macrophages. Cells were excized from the SCS and cortical sinus 
areas representing the afferent and efferent lymphatics, respectively. The cortical 
sinus was selected over the medullary sinus, as lymphocytes primarily enter the 
cortical sinus during egress. RNA from the isolated cells was subjected to a whole-
genome wide microarray to reveal differentially expressed genes among the 
analyzed populations. The results contained a large number of genes that were 
predominantly expressed by the afferent or efferent cell population. These genes 
encoded several different families of molecules, such as chemokines, integrins and 
other regulators of inflammatory pathways. Among the results, Msr1 and Robo4 
were predominantly expressed in the afferent and efferent cell populations, 
respectively. Their expression was validated at the protein level and their role in 
the lymphatics was examined with further studies. (I: Fig. 1a-c, SFig. 1-3, Table 
S1-2) 
5.2 Msr1 is expressed by SCS LECs (I) 
Msr1 is a transmembrane protein that belongs to the Class A scavenger receptors. It 
is predominantly expressed in anti-inflammatory type 2 macrophages, where it 
recognizes modified self and foreign molecules and is involved in their removal. 
Numerous ligands have been reported for Msr1, the most prominent being 
acetylated low-density lipoprotein. (Canton et al., 2013; Kelley et al., 2014) Our 
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microarray revealed Msr1 to be preferentially expressed by the afferent LECs in 
comparison to efferent LECs. Image analysis showed Msr1 staining in the SCS 
floor LECs, while Msr1 could not be detected in cortical sinuses. The lymph node 
medullary sinus stained positively for Msr1; however, the staining could derive 
from both LECs as well as macrophages, in theory. Similar staining patterns for 
Msr1 were detected in the MLN, while Peyer’s patches devoid of afferent 
lymphatics were negative for Msr1. Notably, SSM do not express Msr1 and 
therefore, Msr1 expression in the afferent LECs is not derived from contaminating 
macrophages in the samples subjected for microarray.  (I: Fig. 1d, Fig. 2-3, SFig. 4) 
We wanted to investigate whether Msr1+ afferent lymphatics would be present in 
the periphery and analyzed skin lymphatics with flow cytometry and imaging. 
Msr1 expression in LECs of the skin can be detected, albeit at very low levels. (I: 
Fig. 4, SFig. 5) As this was the first time Msr1 expression has been described in 
LECs, we investigated whether they express the same isoforms of Msr1 as 
macrophages. By analyzing human primary LECs isolated from the skin and lymph 
node as well as monocyte derived macrophages, we were able to detect transcripts 
of isoforms 1 and 2, but not isoform 3, for Msr1 in both cell types. (I: SFig. 7) 
5.3 Msr1 regulates lymphocyte migration in the 
SCS (I) 
During migration to the lymph node via lymphatic vessels, lymphocytes must 
adhere to endothelial cells in the periphery, transmigrate through the LEC layer, 
migrate along the lymphatic vessels and finally, adhere and transmigrate through 
the SCS LEC floor. To study whether Msr1 plays any role in regulating cell 
adhesion, we performed adhesion assays with mouse and human frozen lymph 
node sections as well as primary mouse LECs. Lymph nodes were isolated from 
Msr1 KO, WT mice or humans, and frozen sections were treated with blocking 
antibodies against Msr1 or their isotype controls. Isolated lymphocytes were let to 
bind to the sections and adhered lymphocytes were assessed by microscopy. For 
these experiments, SSMs were depleted from mouse lymph nodes with s.c. 
injections of clodronate containing liposomes to remove the potential effect of 
macrophages on lymphocyte adhesion. In similar experiments, adherence of 
lymphocytes to primary mouse LECs treated with an Msr1-targeting blocking 
antibody or its isotype control was determined. In all cases, binding of lymphocytes 
to the SCS region of lymph nodes, or directly to LECs, was reduced by 60% when 
Msr1-mediated binding was abrogated. Direct binding of Msr1 to B220+ B cells, 
CD4+ T cells as well as CD11b+ myeloid cells, but not CD8+ T cells, was detected 
using an Msr1-Fc fusion protein. (I: Fig. 5b-f, i, SFig. 5a-b) 
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To analyze the role of Msr1 in regulating lymphocyte migration, we performed 
in vivo experiments utilizing Msr1 KO animals. Analyzing lymph nodes from Msr1 
KO mice revealed them to have a comparable lymphocyte composition in 
comparison to their WT controls. Similarly, the lymph node lymphatic and blood 
vasculature appeared normal. (I: Fig. 5a) To study the role of Msr1 in lymphocyte 
migration via the lymphatics, we adoptively transferred CFSE-labeled lymphocytes 
s.c. into Msr1 KO and WT recipient animals and analyzed the migrated 
lymphocytes that were recovered from draining popliteal lymph nodes with flow 
cytometry and fluorescence imaging. Lymphocyte migration appeared normal in 
Msr1 KO animals when analyzing migrated cells 12 hours post adoptive transfer. 
When analyzing the distance of the migrated cells from the SCS at 4.5 hours after 
transfer, lymphocytes in Msr1 KO recipients migrated 30% further into the 
draining lymph node parenchyma in comparison to WT animals. This suggests that 
Msr1 may have a role in promoting retention of lymphocytes in the SCS through 
direct adhesion. (I: Fig. 5g-h, SFig. c-f) 
5.4 Robo4 is expressed in efferent lymphatics (II) 
Robo4 was selected as a target molecule predominantly expressed by the efferent 
lymphatics. Originally, Robo4 was discovered to be expressed in vascular 
endothelial cells (Huminiecki et al., 2002; Okada et al., 2007) and later in primary 
human LECs (Yu et al., 2014). Robo4 belongs to the family of neuronal guidance 
molecules, the roundabout proteins, which consist of four different receptors, 
Robo1-4 (Legg et al., 2008). It has a role in inhibiting angiogenesis and endothelial 
permeability (Jones et al., 2008) as well as in regulating stem cell migration 
(Smith-Berdan et al., 2011, 2015). We studied expression of Robo4 in the 
lymphatics with flow cytometry and fluorescence imaging and were able to detect 
protein level expression of Robo4 in LEC and BEC populations isolated from 
peripheral lymph nodes, MLNs and Peyer’s patches. To image Robo4 expression 
in the lymph node, we produced a monoclonal antibody against murine Robo4 by 
taking advantage of the Robo4 deficient mouse. The generated monoclonal 
antibody was administered s.c. into the footpads of WT mice to label Robo4+ cells 
in the draining lymph node in vivo. Imaging data revealed Robo4 to be located in 
the medullary sinus of the draining lymph node while the SCS LECs were mostly 
devoid of any signal. Robo4 was similarly expressed in human lymph node blood 
vessels and lymphatic sinus LECs as well as in the lymphatic vasculature of the 
appendix, which were observed by traditional immunofluorescence stainings in 
vitro. (II: Fig. 1-2, SFig. 1-2) 
To study the role of Robo4 in efferent lymphatics we concentrated our further 
studies to the Peyer’s patch as it is devoid of afferent lymphatics. Analyses of the 
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proportion and distribution of main lymphocyte subpopulations within the Peyer’s 
patch proved to be comparable between Robo4 KO and WT mice. In comparison, 
the amount of B cells was diminished in peripheral lymph nodes, as was the actual 
number of T cells. The lymphatic vasculature, blood vessels and MAdCAM-1+ 
HEVs appeared normal in Robo4 KO Peyer’s patches. (II: Fig. 3, SFig. 3) 
5.5 Robo4 contributes to the turnover of Peyer’s 
patch naïve B cells (II) 
Similar to Msr1, Robo4 regulates lymphocyte adhesion to the lymphatic sinus of 
human lymph nodes, which were pretreated with antibodies against Robo4 or their 
respective controls. We examined the role of vascular Robo4 in regulating entry of 
lymphocytes into lymph nodes and found Robo4 to regulate the early entry of B 
cells into Peyer’s patches and the MLN as well as the entry of T cells into 
peripheral lymph nodes and MLN at a later timepoint. A concomitant increase of 
adoptively transferred lymphocytes was detected in the peripheral blood of Robo4 
KO mice (2-hour timepoint), whereas the percentage of transferred cells was found 
to be reduced later (18-hour timepoint). (II: Fig. 2d, 4, SFig. 4-6) To study the 
turnover of Peyer’s patch lymphocytes, they were labeled in situ with FITC, and 
the number of lymphocytes remaining in the Peyer’s patches was examined 24 
hours after labeling. These migration experiments revealed that the percentage of 
naïve B cells retained in Robo4 KO mice was enlargened in comparison to their 
WT controls. The endogenous CD19+CD62L+CD44- naïve B cells reside in the 
follicle surrounding GCs in the Peyer’s patch. B cell development in the bone 
marrow was not affected by depletion of Robo4 and analysis of different B cell 
subpopulations recovered from Peyer’s patches revealed no differences among B 
cells in Robo4 KO and their WT controls. Adoptive transfer of lymphocytes into 
the footpads of Robo4 KO mice and their controls suggested that lymphocyte 
egress might be hindered in the absence of Robo4. Interestingly, S1P1 known to 
regulate B cell egress in the Peyer’s patch was expressed less at the mRNA level in 
Robo4 KO B cells. Altogether, these results suggest that Robo4 contributes to the 
turnover of Peyer’s patch B cells. (II: Fig. 5, SFig. 7-9) 
5.6 Robo4 and gut lymphoid tissue homeostasis 
(II) 
We reasoned that the increased amount of retained naïve B cells in Robo4 KO 
Peyer’s patches would cause the tissues to grow unless their cell number would be 
kept constant with complementary apoptosis. We examined the rate of apoptosis 
and discovered that the percentage and number of Annexin V+ early apoptotic cells 
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was slightly increased in Robo4 KO Peyer’s patches. In contrast, end-phase 
apoptotic cells with fragmented DNA detected with the TUNEL staining kit were 
not increased. (II: Fig. 6) Therefore, increased naïve B cell turnover in Robo4 KO 
mice is not markedly compensated for by higher rates of apoptosis. This suggests 
that the size of Robo4 KO Peyer’s patches may gradually increase over time unless 
other factors regulate their cell turnover. 
Examining the tissue weights of Robo4 KO Peyer’s patches and MLNs 
revealed that the mass of MLNs increases in Robo4 KO mice over time. Although 
expected, Peyer’s patches did not show relative increase in their weight. To study 
what might cause growth of MLNs we analyzed different lymphocyte populations 
but found no single population to be drastically increased. Analysis of apoptotic 
cells revealed that in fact, Robo4 KO mice exhibit more dead cells among 
lymphocytes in their MLNs. As hematopoietic cells did not offer any explanation 
to the phenomenon, we examined the stromal compartment. The largest population 
of stromal cells is the FRCs that ensheath the collagen-rich reticular conduit. 
Stainings and image quantification of collagen I revealed a marked increase in 
collagen I+ staining in the MLNs of Robo4 KO mice, which may offer a reasonable 
explanation for the observed increase in tissue weight. (II: Fig. 7) 
 
Figure 6.  Lymph nodes and their draining patterns relevant to study III. Antibodies and other in 
vivo administered reagents were injected subcutaneously (s.c.) into the footpads of 
recipient mice. Entry of antibodies into the draining (popliteal) and non-draining 
(contralateral popliteal, inguinal or axillary) lymph nodes were examined. In some 
cases, the second lymph node in the chain (lumbar, also known as sacral) was 
analyzed. Arrows indicate the direction of lymphatic drainage. Figure adapted from 
Kawashima et al., 1964. 
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5.7 Transfer of antibodies into the draining lymph 
node parenchyma (III) 
The prevailing dogma has been that small soluble antigens under 70 kDa enter the 
lymph node conduit, whereas large antigens over 70 kDa are transported to lymph 
nodes only within migratory DCs (Mueller and Germain, 2009). We detected that a 
pool of s.c. administered fluorescently conjugated antibodies (size 150 kDa) 
against B cells (B220), helper T cells (CD4), endothelial cells (CD31) and DCs 
(CD11c) were instantly and locally transferred into the parenchyma of draining 
lymph nodes. Antibodies remained intact and were able to bind their native 
epitopes, which was detected by flow cytometry and fluorescence imaging. The 
administered antibodies could be detected only from the single draining lymph 
node (popliteal), or the next node along the chain (lumbar, Figure 6). Antibodies 
were not present in any non-draining lymph nodes (inguinal, axillary) highlighting 
the function of the peripheral lymphatic vessels, which transported the antibodies 
to the draining lymph node. Experimentally administered antibodies entered the 
lymph node cortex and paracortex readily, however, their penetration into B cell 
follicles was not complete, nor were they able to reach the lumen of HEVs. (III: 
Fig. 1, SFig. 1) 
The transfer of antibodies from the SCS into the parenchyma occurred in a 
dose-dependent manner. Transfer was extremely efficient and antibodies could be 
detected in draining lymph nodes 30 seconds after having been administered. 
Antibody transfer was independent of the target antigen, host or fluorochrome. 
However, the size of antibodies limited their entry into the lymph node as IgM 
antibodies (size 900 kDa) were excluded from the parenchyma. (III: Fig. 2, SFig. 
3) 
5.8 Antigens are transported in fluid phase (III) 
To begin dissecting the mechanism regulating the transport of antibodies across the 
SCS, we examined whether neonatal Fc receptor (FcRn, Fcgrt) known to transport 
IgG antibodies across the placenta and neonatal gut epithelium (Pyzik et al., 2015) 
would regulate transport. According to data generated by the Immunological 
Genome Project, Fcgrt is abundantly expressed in LECs. However, s.c. delivered 
antibodies were transported into the draining lymph nodes of FcRn KO mice as 
efficiently as into their WT controls. Blocking FcRIIb (Fcgr2b) with a function-
blocking antibody did not inhibit transfer of antibodies. Transport was also not 
regulated by the Fc tail of antibodies, as its deglycosylation or absence did not 
affect the outcome. (III: Fig. 3a–b, d, SFig. 4a–d, f) Complement receptors had no 
role in transporting antibodies since s.c. administered IgA and IgY, which is not 
bound by any mammalian Fc or complement receptor, were able to enter the 
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parenchyma. To investigate whether antibody transport is dependent on receptors, 
we s.c. delivered the pool of test antibodies in the presence of competing 
antibodies. These experiments revealed antibody transport across the SCS to be 
receptor independent. (III: Fig. 3c, e, SFig. 4e, g-i) 
Fluorescence imaging of an in situ fixed, nonbinding unconjugated rat IgG2a 
antibody (referred to as free antibody) revealed that the transferred antibody 
colocalized with the SCS floor LECs. Moreover, it was detectable between 
lymphocytes of the lymph node parenchyma suggesting the antibody to float freely 
in the interstitium. The free antibody created a centrifugal concentration gradient 
with the highest concentration directly under the SCS. Similarly, s.c. administered 
fluorescently labeled dextrans (70 and 500 kDa in size) were transferred into the 
lymph node parenchyma, displayed a concentration gradient and surrounded 
parenchymal lymphocytes. These results indicated that antibodies and other model 
antigens are transported across the SCS floor in fluid-phase. (III: Fig. 4) 
5.9 LECs transcytose antigens across the SCS (III) 
The known mechanisms for antigen transport from the SCS to the lymph node 
parenchyma are the reticular conduit and SSMs, which neither regulated 
transcytosis of antibodies. (III: Fig. 5–6) Endothelial cells are known to actively 
transport macromolecules from one surface to the other using transcellular 
vesicular transport, i.e. transcytosis, which has been reported in BECs (Fung et al., 
2018; Yazdani et al., 2019) and LECs in the intestine and skin (Dobbins and 
Rollins, 1970; Triacca et al., 2017). We asked whether SCS LECs would transport 
lymph-borne antibodies and observed LECs to be rich in heterogenous vesicular 
structures determined with electron microscopy. The lymph-borne free antibody 
localized within these vesicles of the SCS LECs while intercellular junctions were 
devoid of the antibody. High-resolution imaging demonstrated free antibody 
vesicles in the CD31+ SCS floor LECs, where they localized within or in direct 
contact with endosomes expressing the early endosomal marker EEA1. (III: Fig. 7, 
SFig. 5, Supplemental Video 1) 
Endocytosis involves the generation of small vesicular structures formed from 
the plasma membrane, which transport cargo into the cell cytoplasm. Known 
pathways of endocytosis are macropinocytosis, clathrin-dependent, caveolin-
dependent and clathrin-independent endocytosis. Dynamin is required for the 
releasing of the endocytic vesicle from the plasma membrane. (Doherty and 
McMahon, 2009; Ferreira and Boucrot, 2018; Kaksonen and Roux, 2018) To 
describe the mechanism regulating transcytosis of antibodies, we experimentally 
manipulated the known endocytic pathways. The pool of test antibodies was s.c. 
administered into Cav1 KO mice, where we observed intact transport of antibodies 
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into the lymph node parenchyma. Chemical inhibitors disrupting clathrin-mediated 
endocytosis (Pitstop 2, monodansylcadaverine), macropinocytosis (EIPA, 
imipramine) and function of dynamin (Dyngo-4a, Dynole 34-2) were administered 
topically in vivo on surgically exposed lymph nodes to block the respective 
pathways. In addition, intercellular junctions were stabilized with the topical 
administration of adrenomedullin in vivo. After inhibition, the pool of test 
antibodies was delivered s.c. and the entry of antibodies into the lymph node 
parenchyma was detected with flow cytometry or fluorescent imaging. No 
abrogation of antibody transport was observed, except after the administration of 
the dynamin blocking inhibitors Dyngo-4a and Dynole 34-2. Our results describe 
LECs as the cells mediating active dynamin-dependent, fluid-phase transcytosis of 
antibodies across the SCS into the lymph node parenchyma. (III: Fig. 8–9, SFig. 6) 
5.10 Applications for s.c. administered antibodies 
(III) 
We reasoned that LEC-mediated transcytosis would transport other protein 
antigens into the lymph node similar to antibodies. Indeed, an s.c. delivered human 
protein was detected 2 hours after injection in lymph node resident DCs and 
macrophages, suggesting that immune reactions can start immediately after 
antigens get access to the lymph node parenchyma. (III: Fig. 10) We were also able 
to locally activate T cells in the draining lymph node by s.c. administering 
antibodies binding to the T cell receptor and CD3, and by detecting the increased 
amount of T cell activation markers CD69 and CD25. T cell activation was also 
examined using an adoptive transfer model, where naïve CD45.2+ CD4+ T cells 
expressing the transgenic T cell receptor for OVA (OTII cells) were isolated, 
labeled with CFSE and introduced intravenously into CD45.1+ congenic recipients. 
OVA was administered with a T cell activating (clone D665) or inhibiting (clone 
37.51) anti-CD28 antibody, a negative IgG or positive LPS control. Three days 
later the draining popliteal lymph nodes were isolated and the proliferation of T 
cells was examined with flow cytometry. When OTII+ T cells were activated with 
clone D665, they proliferated specifically in the draining lymph node, whereas 
administration of the CD28 inhibiting clone 37.51 reduced the proliferation of 
OVA-specific T cells. Finally, the activating (clone D665) and inhibiting (clone 
37.51) anti-CD28 antibodies were s.c. administered into different legs of the same 
recipient animal, where they exerted the same local activating and inhibiting 
functions. (III: Fig. 11b–g, SFig. 7d–e) 
Whole-organ imaging of optically cleared tissues reveals a tremendous amount 
of information on tissue anatomy. However, sample preparation is time consuming 
and usually requires overnight staining of each primary and secondary antibody. 
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(Susaki and Ueda, 2016) We sought out to test whether the transport of lymph-
borne antibodies into the draining lymph node parenchyma could be utilized to 
improve whole mount imaging. The pool of test antibodies against B cells (B220), 
helper T cells (CD4), endothelial cells (CD31) and DCs (CD11c), was 
administered s.c. and the draining lymph nodes were harvested after 30 min. 
Samples were lightly fixed, optically cleared using a mixture of benzyl alcohol and 
benzyl benzoate (BABB), and imaged immediately with a confocal microscope. 
Imaging the lymph nodes revealed that LEC mediated transcytosis can be 
harnessed to expedite the preparation of whole mount samples reducing sample 
preparation from days to a couple of hours. (III: Fig. 11a, Supplemental video 2) 
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6 Discussion 
6.1 Heterogeneity of lymph node LECs (I) 
The lymph node contains LECs at its sinuses, where they are in direct contact with 
migrating cells and lymph contents. We analyzed the molecular differences of the 
afferent and efferent LECs in the lymph node SCS and lymphatic sinus. The 
determined cell populations were isolated with laser capture microdissection and 
cell sorting and subjected to a genome-wide microarray. The methods and markers 
used for isolating the samples did not yield pure LEC populations. Namely, cells 
were sorted based on positive expression of podoplanin without the endothelial 
marker CD31 or exclusion of FRCs. Laser capture microdissection, like any 
method, also has its limitations. Most likely, the cell samples isolated by manual 
excision contain material from other SCS cells, such as macrophages and 
lymphocytes. Therefore, combining the two isolation methods is essential, as is the 
thorough validation of the hit molecules. 
Heterogeneity of immune cells is under heavy investigation. Many of the 
lymph node cell populations, such as FRCs, have been subjected for microarray 
analyses and published as part of the Immunological Genome Project (Malhotra et 
al., 2012). Genome-wide microarrays have been followed by deep sequencing 
techniques such as RNA sequencing, which is able to detect previously unknown 
genes as well as genetic polymorphisms and isoforms (Malone and Oliver, 2011). 
Currently, single-cell sequencing has emerged as a leading-edge technique 
allowing unbiased analysis of samples, where the analyzed cells are clustered 
according to their transcriptome. Although the method is highly sensitive and 
reveals a great amount of new genetic information, single-cell sequencing does not 
yield spatial information of the analyzed genes. In addition, it cannot be used for 
detecting non-coding or bacterial RNA. (Papalexi and Satija, 2017) Recently, two 
studies reporting single-cell sequencing of the mouse lymph node LECs were 
published. Lymph node LECs were reported to cluster into valve, SCS ceiling, SCS 
floor and two separate clusters of medullary sinus LECs. (Fujimoto et al., 2020; 
Xiang et al., 2020) Human lymph node LEC heterogeneity was also recently 
reported (Takeda et al., 2019). Our research compared the differentially expressed 
genes between two LEC populations using a more conventional microarray. These 
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results can now be examined and compared to data generated by single-cell 
sequencing to validate our findings. 
6.2 Msr1 and Robo4 – newly described lymphatic 
markers (I, II) 
Based on our microarray results, we selected Msr1 and Robo4 for functional 
studies. Msr1 is a scavenger receptor originally reported to be expressed in 
macrophages, where one of its functions is to recognize and remove pathogens and 
other foreign substances (Kelley et al., 2014). We discovered Msr1 to be expressed 
in the SCS LECs, while cortical sinus LECs were negative. Interestingly the 
medullary sinus stains positive for Msr1. As the medullary sinus contains LECs as 
well as macrophages and DCs, which may also express Msr1, flow cytometry 
analysis of medullary sinus LECs can verify whether they truly express Msr1. 
Based on single-cell sequencing, medullary sinus LECs cluster as a separate 
population from cortical sinus LECs (Fujimoto et al., 2020; Xiang et al., 2020). 
Therefore, it may well be possible that Msr1 expression is differently regulated by 
LECs of the cortical and medullary sinus. 
Robo4 expression in the lymphatics was validated using flow cytometry and 
fluorescence imaging with an in-house antibody. Peripheral lymph nodes and the 
MLN displayed heterogeneous expression of Robo4 among LECs, whereas Robo4 
was homogeneously expressed in Peyer’s patch lymphatics. In humans, Robo4 is 
highly expressed in the vasculature of several solid tumors, such as melanoma, 
renal, lung and liver cancer, while it is absent from normal tissue. Most likely 
Robo4 expression is induced by low shear stress, which would explain why healthy 
blood vessels do not express Robo4. (Mura et al., 2012; Seth et al., 2005) Due to its 
expression in tumor tissue, Robo4 has been studied as a drug target. Vaccinations 
against Robo4 reduce tumor growth in lung carcinoma (Zhuang et al., 2014) and 
Robo4 can be utilized for the delivery of anti-tumor therapy using Robo4-detecting 
antibodies (Yoshikawa et al., 2013). Robo4 is also expressed in several 
subpopulations of human lymph node LECs (Takeda et al., 2019). Therefore, anti-
tumor therapy utilizing Robo4 as an address molecule may guide cancer drugs to 
lymph nodes, where they could be available to reduce tumor metastases. 
Alternatively, the delivery of tumor cell attacking drugs into lymph nodes could 
give rise to adverse effects. 
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6.3 Msr1 and Robo4 regulate lymphocyte 
migration (I, II) 
Cell migration across the SCS is known to be regulated by several molecules 
(Martens et al., 2020; Rantakari et al., 2015; Ulvmar et al., 2014). We discovered 
that Msr1 is another regulator of lymphocyte entry from the SCS into the lymph 
node parenchyma. In the absence of Msr1, lymphocytes migrated significantly 
further into the lymph node parenchyma 4.5 hours after their adoptive transfer, 
when compared to their controls. This suggests that Msr1 may function as a 
retaining molecule in SCS LECs regulating the early migration of lymphocytes 
through their adhesion to LECs. We also observed adoptively transferred WT 
lymphocytes in the medullary sinus of the lymph node, as reported by others 
(Braun et al., 2011). Msr1 expressed in the medullary sinus may take part in 
regulating lymphocyte migration into the lymph node parenchyma. In the case of 
Robo4, we detected it to regulate lymphocyte entry via HEVs to examined 
lymphoid tissues as well as the turnover of naïve B cells in Peyer’s patches. As 
Msr1 and Robo4 can both mediate direct binding of lymphocytes to the lymph 
node sinuses, they may directly have a role in regulating lymphocyte migration by 
providing retention of lymphocytes. An indirect role via other receptors or cell 
types can also be the underlying mechanism. 
We discovered little differences in the lymphocyte compositions of the 
peripheral lymph nodes of Msr1 and Robo4 KO mice at homeostatic conditions. 
The fact that these mice appeared rather normal suggests that lymphocyte 
migration into lymph nodes is not greatly disrupted. As a drastic comparison, 
plt/plt mice, which have a naturally occurring mutation resulting in the complete 
lack of CCL19 and CCL21, have a very small count of T cells in their lymph nodes 
(Nakano et al., 1997). All of our studies were performed using full KO mice with 
the genes of interest depleted in all cells and throughout the whole lifespan of the 
animal. Hence, it is plausible that compensatory mechanisms arise in the KO 
animals, which may mask the effect of Msr1 or Robo4. Utilizing conditional 
knockout animals created with the Cre-loxP system would specifically allow 
investigating the role of Msr1 and Robo4 solely in LECs. As Msr1 is expressed by 
LECs as well as cells of hematopoietic origin, another approach would be creating 
bone marrow chimeras by reconstituting WT recipients with Msr1 KO bone 
marrows allowing for the analysis of LEC specific Msr1. 
Lymphocyte migration involves both the migrating cell and its surrounding 
tissue. In most of our adoptive transfer experiments, we transferred WT cells into 
Msr1 or Robo4 deficient host animals. However, when studying the turnover of B 
cells in Robo4 KO Peyer’s patches, we were in fact studying the turnover of 
endogenous B cells in their natural environment. Robo4 is expressed by 
hematopoietic stem cells in the bone marrow, and its mRNA expression decreases 
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during lymphocyte maturation (Smith-Berdan et al., 2011). While lymphocytes do 
not express Robo4 mRNA, the effects of its expression during the stem cell phase 
may regulate other molecules. We studied mRNA expression of Cxcr4, Cxcr5 and 
S1pr1 in Peyer’s patch B cells. All these genes have been reported to be important 
in regulating lymphocyte egress in the Peyer’s patch (Pham et al., 2010; Schmidt et 
al., 2013). As an unexpected finding, the level of S1pr1 expression was diminished 
in Robo4 KO mice. Therefore, changes in the gene signature of the migrating 
lymphocytes in Robo4 KO animals may contribute to the impairment in the 
detected B cell turnover. 
During inflammation, the lymph node faces drastic changes as LECs and other 
stromal cells undergo massive expansion to facilitate the increased number of 
proliferating lymphocytes. In addition, lymphocyte migration into lymph nodes is 
increased; lymphocyte egress is shut down and the molecular composition of 
endothelial cells changes. (Thierry et al., 2019) Studies of Msr1 and Robo4 as 
regulators of lymphocyte migration were conducted under homeostasis and their 
possible role during inflammation remains to be analyzed. However, Msr1 may 
well exert scavenging functions in endothelial cells, which has been reported for 
another scavenger receptor, CD36 (Huang et al., 2019). Endothelial Robo4 has 
been studied during inflammation, where it has anti-inflammatory properties (Zhao 
et al., 2014), it suppresses endothelial hyperpermeability (Shirakura et al., 2019) 
and regulates cellular crosstalk between endothelial cells and monocytes (Shirakura 
et al., 2017). Similarly, Robo4 may have a more marked role in regulating 
lymphocyte migration or other LEC-mediated functions during inflammatory 
conditions. 
6.4 Robo4 contributes to MLN homeostasis (II) 
When studying the turnover of B cells in Robo4 KO mice, we reasoned that the 
observed increase of B cells would eventually result in larger Peyer’s patches if not 
compensated for by apoptosis. We observed a small increase in the number of early 
apoptotic cells (Annexin V+) among CD45+ hematopoietic cells, yet, the number of 
late apoptotic cells was not increased based on the TUNEL assay, which detects 
fragmented DNA. This discrepancy may be due to the different methods used for 
detection. The whole number of apoptotic cells can be analyzed easily with flow 
cytometry, whereas imaging only concentrates on a single plane of the tissue. It is 
also possible that apoptosis may be differentially regulated in Robo4 KO mice, and 
our methods did not detect this highly dynamic process. 
Unexpectedly, we observed a change in the size of MLNs in Robo4 KO mice. 
There was a significant increase in tissue growth among adult Robo4 KO mice 
(>12 weeks of age) in comparison to their WT controls, and we sought out to 
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investigate what might cause this prominent 20% increase in tissue weight. No 
differences explaining the phenomenon were detected among the studied immune 
cells in the MLNs. Therefore, we investigated whether there were any changes in 
the stroma and concentrated on FRCs, which are the most abundant stromal cells. 
To visualize the conduit ensheathed by FRCs, we stained and quantified collagen I+ 
signal in MLNs of Robo4 KO and their WT counterparts. Surprisingly, the amount 
of collagen I was markedly increased in the MLNs of Robo4 KO mice suggesting 
an increase in the amount of FRCs or in their synthesis of collagen. Robo4 is not 
expressed in FRCs according to Immunological Genome Project data, nor could we 
detect Robo4+ FRCs in the peripheral lymph node. Hence, Robo4 on other cell 
types may indirectly regulate the tissue environment in the MLN favoring an 
increased deposition of collagen. Indeed, crosstalk between different stromal cell 
compartments or between stromal cells and immune cells has been previously 
reported. FRCs are known to regulate vascular cell permeability via production of 
VEGF (Chyou et al., 2008) and they may also regulate production of ECM 
molecules in response to contact with lymphocytes (Katakai et al., 2004). 
6.5 Large antigens are transported into the lymph 
node parenchyma (III) 
The filtering function of the lymph node has been well documented in plenary 
publications, which also determined the size limit of soluble molecules physically 
able to enter the reticular conduit (Gretz et al., 2000; Sixt et al., 2005). Challenging 
the widely accepted limits of size-selective filtering at the SCS, we discovered that 
large lymph-borne antigens with a size at least up to 500 kDa could enter the 
lymph node parenchyma. Resident DCs have been shown to sample the conduit 
content and directly acquire antigens from there (Sixt et al., 2005). However, 
transcytosed antigens are also available for DCs directly in the lymph node 
parenchyma. As lymph is full of proteins derived from the organs it drains 
(Clement and Santambrogio, 2013) as well as endogenous antibodies (Leak et al., 
2004; Worm, 1981), all of these molecules are instantly drained from the periphery 
into the lymph node, where they are available for immune cells. 
Although the filtering function of the lymph node has been thoroughly 
documented, the presence of parenchymal antibodies or other large antigens has 
not previously been reported. Parenchymally transported antibodies and dextrans 
can easily remain under the detection limit if not specifically studied. Transport of 
antigens into the lymph node parenchyma has been observed before, although the 
doses of administered antibodies have been large and transport was observed over 
several minutes to hours in comparison to our observations in 30 seconds. 
Moreover, no molecular mechanism describing the phenomenon was reported. 
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(Gerner et al., 2017; Hauser et al., 2007; Pape et al., 2007; Roozendaal et al., 2009) 
Combining imaging with flow cytometry allowed us to directly verify the binding 
of s.c. administered antibodies to lymph node parenchymal lymphocytes 
confirming our results. Moreover, we were able to physically visualize the free 
antibody within SCS floor LECs, where it colocalized with EEA1+ endosomes. 
Whether transport of antigens and antibodies increases during inflammation 
remains to be studied. In vitro studies have reported that transcytosis in peripheral 
LECs increases during flow and inflammatory stimuli (Triacca et al., 2017), 
therefore inflammation-induced changes may also increase the levels of large 
antigen or antibody transcytosis in the lymph node. 
 
Figure 7. Mechanism for the transfer of large lymph-borne soluble antibodies across the 
subcapsular sinus (SCS). Lymphatic endothelial cells (LEC) actively transcytose 
antibodies and other antigens from the SCS lumen to the lymph node parenchyma. 
Fluid-phase transcytosis is dynamin dependent and most likely resembles ultrafast 
endocytosis independent of other described mechanisms of endocytosis. 
6.6 Active vesicular transcytosis in LECs (III) 
LECs transport lymph-borne antibodies across the SCS by fluid-phase dynamin-
dependent transcytosis (Figure 7). If LECs were once viewed as just endothelial 
cells passively lining lymph node sinuses, recent research has highlighted them as a 
multifunctional cell population of the lymph node (Jalkanen and Salmi, 2020). 
Endocytosis in endothelial cells was first described for BECs. Yet, early electron 
microscopy studies already recognized vesicular structures in LECs of intestinal 
villi, where vesicles accounted for 15% of the cytoplasm volume and transported 
water-soluble molecules (Dobbins and Rollins, 1970). Peripheral afferent LECs 
have been reported to endocytose albumin and 70 kDa dextrans. This vesicular 
transport plays a significant role in transporting fluids and is mediated by dynamin-
dependent, clathrin- and caveolae-mediated endocytosis. (Triacca et al., 2017) 
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We observed lymph node LECs to be rich in vesicular structures in agreement 
with reports from other organs. The mechanism of LEC-mediated transcytosis was 
determined as dynamin-dependent, caveolin and clathrin-independent endocytosis 
as a sum of several observations. The role of caveolae was excluded, as antibody 
transport was intact in Cav1 KO mice. Receptor-independence of antibody 
transport suggests that clathrin, which is known to be triggered by receptor ligation, 
is not involved. In addition, the formation of clathrin-coated vesicles takes up to 
30-120 seconds. Macropinocytosis also requires receptor activation and should be 
visible due to the large size of macropinocytic vesicles (0.2-10 µm). (Kaksonen 
and Roux, 2018) We interfered with the different endocytic pathways by utilizing 
chemical inhibitors. All results combined, our data strongly suggests LEC-
mediated transcytosis to be a previously unknown, extremely fast mechanism of 
transport, which resembles ultrafast clathrin-independent endocytosis (Watanabe 
and Boucrot, 2017). Antibodies are most likely not excluded from other vesicles 
and therefore, may also be endocytosed passively by other pathways. 
The SCS floor is formed by LECs located on top of the ECM, macrophages 
and DCs. The discontinuous ECM of the SCS floor was thought to allow diffusion 
of antigens into the lymph node parenchyma over time (Pape et al., 2007), although 
they were most likely transcytosed into the parenchyma by LECs. In theory, 
antibodies might also get access into the lymph node parenchyma through 
intercellular junctions. Our analyses revealed intercellular junctions to be devoid of 
the free antibody, neither did the junction-stabilizing chemical, adrenomedullin, 
prevent transport of antibodies into the lymph node parenchyma. LEC intercellular 
junctions have been reported to comprise of tight junctions (Pfeiffer et al., 2008), 
however, SCS floor LECs were not analyzed in the study. Thus, it remains unclear 
what kind of junctions govern the floor of the SCS and whether it is physically 
possible for antibodies to flow through them. 
6.7 Therapeutic applications for lymphatic 
transport of antibodies (III) 
Therapeutic antibodies are increasingly used to treat cancer, chronic inflammatory 
and autoimmune diseases. Novel checkpoint inhibitors, i.e. monoclonal antibodies 
targeting CTLA4, PD-1 or PD-L1, have had a growing impact on the treatment of 
cancer. However, their delivery to solid tumors is challenging and systemic 
administration of these antibodies causes severe side effects, such as autoimmunity, 
cytokine release and vascular leakage syndromes. Hence, the development of new 
delivery strategies is crucial to allow efficient delivery of therapeutic antibodies 
into solid tumors while minimizing adverse effects. (Riley et al., 2019) By 
exploiting the natural draining function of the lymphatic vasculature in the skin, 
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s.c. administered biologically active antibodies can be directly delivered to all cells 
in the lymph node. Moreover, we demonstrated that antibodies exert only local 
functions in the draining lymph node while leaving other lymph nodes intact. S.c. 
administration of therapeutic antibodies would enable using lower antibody doses 
and restrict the effector functions of antibodies only to the draining lymph nodes. 
Moreover, solid tumors are known to metastasize into draining lymph nodes via the 
lymphatics (Alitalo and Detmar, 2012). Based on our results, low doses of tumor 
cell-depleting therapeutic antibodies could be delivered s.c. into the peritumoral 
space, where lymphatic vessels would transport them into the same draining lymph 
node as any metastases. 
Another therapeutic approach for the s.c. delivery of antibodies is 
immunoactivation. We demonstrated that T cell activation could be stimulated or 
inhibited in the draining lymph node with the appropriate antibodies via s.c. 
administration. This suggests that immunoactivating antibodies could also be 
utilized for stimulating immune responses against foreign antigens in the draining 
lymph node. This would allow the development of antibody-based vaccines using 
therapeutic immunoactivating antibodies already available for patient care.  
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7 Conclusions 
This study describes new lymphatic molecules that take part in regulating 
lymphocyte migration in the lymph node and Peyer’s patches. Moreover, we 
describe how lymph node LECs transport lymph-borne large antigens and 
antibodies into the draining lymph node parenchyma, where they are available for 
immune cell activation or effector fuctions. The obtained results broaden the 
current view regarding molecules that regulate cell migration. In addition, the 
discovery of new functions for LECs sheds light on the filtering function of the 
lymph node. The findings of this study can be summarized in the following way: 
1. Lymph node sinus LECs differ in the genes they express. 
2. Msr1 is expressed in the lymph node SCS LECs, where it regulates 
migration of lymphocytes into the lymph node via the afferent 
lymphatics. 
3. Robo4 regulates B cell turnover in Peyer’s patches in addition to 
maintaining homeostasis in the MLN. 
4. LECs transport large lymph-borne antigens and antibodies from the SCS 
into the draining lymph node parenchyma via fluid-phase dynamin 
dependent transcytosis. 
5. Subcutaneously administered antibodies are delivered to the draining 
lymph node in a functionally intact form, which can be utilized for 
efficient delivery of therapeutic antibodies and local immunomodulation. 
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